<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83107</article-id><article-id pub-id-type="doi">10.7554/eLife.83107</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group></article-categories><title-group><article-title>The evolutionary mechanism of non-carbapenemase carbapenem-resistant phenotypes in <italic>Klebsiella</italic> spp</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-293569"><name><surname>Rosas</surname><given-names>Natalia C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2343-2394</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-293420"><name><surname>Wilksch</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-293421"><name><surname>Barber</surname><given-names>Jake</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9279-7763</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293550"><name><surname>Li</surname><given-names>Jiahui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293551"><name><surname>Wang</surname><given-names>Yanan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293552"><name><surname>Sun</surname><given-names>Zhewei</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293553"><name><surname>Rocker</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-221646"><name><surname>Webb</surname><given-names>Chaille T</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293555"><name><surname>Perlaza-Jiménez</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-221650"><name><surname>Stubenrauch</surname><given-names>Christopher J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4388-3184</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292543"><name><surname>Dhanasekaran</surname><given-names>Vijaykrishna</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3293-6279</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145059"><name><surname>Song</surname><given-names>Jiangning</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177327"><name><surname>Taiaroa</surname><given-names>George</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293558"><name><surname>Davies</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58864"><name><surname>Strugnell</surname><given-names>Richard A</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293556"><name><surname>Bao</surname><given-names>Qiyu</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-293557"><name><surname>Zhou</surname><given-names>Tieli</given-names></name><email>wyztli@163.com</email><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-212034"><name><surname>McDonald</surname><given-names>Michael J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5735-960X</contrib-id><email>mike.mcdonald@monash.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-285190"><name><surname>Lithgow</surname><given-names>Trevor</given-names></name><email>trevor.lithgow@monash.edu.au</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>Centre to Impact AMR, Monash University</institution></institution-wrap><addr-line><named-content content-type="city">Clayton</named-content></addr-line><country>Australia</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>Infection Program, Biomedicine Discovery Institute and Department of Microbiology, Monash University</institution></institution-wrap><addr-line><named-content content-type="city">Clayton</named-content></addr-line><country>Australia</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>School of Biological Sciences, Monash University</institution></institution-wrap><addr-line><named-content content-type="city">Clayton</named-content></addr-line><country>Australia</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rd5t069</institution-id><institution>The First Affiliated Hospital of Wenzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Wenzhou</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02bfwt286</institution-id><institution>Infection Program, Biomedicine Discovery Institute and Department of Biochemistry &amp; Molecular Biology, Monash University</institution></institution-wrap><addr-line><named-content content-type="city">Clayton, Victoria</named-content></addr-line><country>Australia</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rd5t069</institution-id><institution>Wenzhou Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Wenzhou</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>School of Public Health, LKS Faculty of Medicine, The University of Hong Kong</institution></institution-wrap><addr-line><named-content content-type="city">Hong Kong Special Administrative Region</named-content></addr-line><country>China</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>Department of Microbiology and Immunology, The Peter Doherty Institute, The University of Melbourne</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ogbunugafor</surname><given-names>C Brandon</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Perry</surname><given-names>George H</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04p491231</institution-id><institution>Pennsylvania State University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>06</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83107</elocation-id><history><date date-type="received" iso-8601-date="2022-08-31"><day>31</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-06-16"><day>16</day><month>06</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-08-30"><day>30</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.30.505938"/></event></pub-history><permissions><copyright-statement>© 2023, Rosas, Wilksch, Barber et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Rosas, Wilksch, Barber et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83107-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83107-figures-v1.pdf"/><abstract><p>Antibiotic resistance is driven by selection, but the degree to which a bacterial strain’s evolutionary history shapes the mechanism and strength of resistance remains an open question. Here, we reconstruct the genetic and evolutionary mechanisms of carbapenem resistance in a clinical isolate of <italic>Klebsiella quasipneumoniae</italic>. A combination of short- and long-read sequencing, machine learning, and genetic and enzymatic analyses established that this carbapenem-resistant strain carries no carbapenemase-encoding genes. Genetic reconstruction of the resistance phenotype confirmed that two distinct genetic loci are necessary in order for the strain to acquire carbapenem resistance. Experimental evolution of the carbapenem-resistant strains in growth conditions without the antibiotic revealed that both loci confer a significant cost and are readily lost by de novo mutations resulting in the rapid evolution of a carbapenem-sensitive phenotype. To explain how carbapenem resistance evolves via multiple, low-fitness single-locus intermediates, we hypothesised that one of these loci had previously conferred adaptation to another antibiotic. Fitness assays in a range of drug concentrations show how selection in the antibiotic ceftazidime can select for one gene (<italic>bla</italic><sub>DHA-1</sub>) potentiating the evolution of carbapenem resistance by a single mutation in a second gene (<italic>ompK36</italic>). These results show how a patient’s treatment history might shape the evolution of antibiotic resistance and could explain the genetic basis of carbapenem-resistance found in many enteric-pathogens.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>antimicrobial resistance</kwd><kwd>non-carbapenemase carbapenem resistance</kwd><kwd><italic>Klebsiella quasipneumoniae</italic></kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>1092262</award-id><principal-award-recipient><name><surname>Lithgow</surname><given-names>Trevor</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Genetic, phenotypic, and evolutionary analysis of a clinical isolate provides an explanation of the intricate genetic factors behind non-carbapenemase carbapenem resistance and sheds light on the evolutionary mechanisms that influence the molecular basis of antibiotic resistance.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Understanding the genetic and evolutionary provenance of antimicrobial resistance (AMR) will be important for developing strategies that slow or prevent the evolution of untreatable pathogens. In the case of bacterial pathogens, there is mounting evidence that the source of antibiotic resistance can be the patient’s own microbiome (<xref ref-type="bibr" rid="bib79">Stracy et al., 2022</xref>) and that treatment history, as well as pathogen genotype, should be taken into account when designing a treatment plan. Carbapenems are a class of β-lactam antibiotics typically reserved for high-risk, multidrug-resistant infections (<xref ref-type="bibr" rid="bib22">Doi, 2019</xref>; <xref ref-type="bibr" rid="bib56">Meletis, 2016</xref>). Surveillance studies show that carbapenem-resistant Enterobacteriaceae (CRE), especially various species of the pathogen <italic>Klebsiella,</italic> have become a widespread problem in clinical settings around the globe (<xref ref-type="bibr" rid="bib34">Hansen, 2021</xref>; <xref ref-type="bibr" rid="bib40">Hu et al., 2016</xref>; <xref ref-type="bibr" rid="bib48">Logan and Weinstein, 2017</xref>).</p><p>There are two general mechanisms of carbapenem resistance. The first and readily diagnosable mechanism is the acquisition of a single gene encoding a carbapenemase enzyme that directly inactivates the antibiotic. The second mechanism requires multiple genetic loci, and bacterial strains in this category often have an over expressed β-lactamase and/or an overexpressed efflux pump and/or an inactivated outer membrane protein (<xref ref-type="bibr" rid="bib56">Meletis, 2016</xref>; <xref ref-type="bibr" rid="bib17">Codjoe and Donkor, 2017</xref>; <xref ref-type="bibr" rid="bib25">Elshamy and Aboshanab, 2020</xref>), and potentially as yet unidentified loci as well. Of these two mechanisms, most carbapenem-resistant <italic>Klebsiella pneumoniae</italic> that have been identified so far are caused by carbapenemases. Like other β-lactamases, carbapenemases can be recognised by sequence analysis (<xref ref-type="bibr" rid="bib84">Wang et al., 2021</xref>), and there are two structurally distinct classes of carbapenemases: the first is the metallo-β-lactamases a family of enzymes that contains a metal ion (usually zinc) coordinated in the active site, a classic example of which is NDM-1 (<xref ref-type="bibr" rid="bib42">Khan et al., 2017</xref>). The second carbapenemase family does not coordinate a metal ion but instead relies on an active site serine to hydrolyse carbapenem drugs (<xref ref-type="bibr" rid="bib17">Codjoe and Donkor, 2017</xref>; <xref ref-type="bibr" rid="bib60">Nordmann and Poirel, 2019</xref>). This second class of carbapenemase includes the IMI, OXA-48, and GES enzymes in addition to the archetypal <italic>K. pneumoniae</italic> carbapenemases: the KPC enzymes (<xref ref-type="bibr" rid="bib60">Nordmann and Poirel, 2019</xref>; <xref ref-type="bibr" rid="bib66">Rapp and Urban, 2012</xref>; <xref ref-type="bibr" rid="bib92">Yigit et al., 2001</xref>) that include the prevalent KPC-2. The KPC-2 carbapenemase has become widespread, found in many clinical investigations of CRE, and the gene encoding this enzyme - <italic>bla</italic><sub>KPC-2</sub> - is transferred readily by horizontal gene transfer via plasmids (<xref ref-type="bibr" rid="bib9">Bowers et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Hardiman et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Kitchel et al., 2009</xref>; <xref ref-type="bibr" rid="bib64">Petrella et al., 2008</xref>; <xref ref-type="bibr" rid="bib90">Wyres et al., 2019</xref>). Since this is a monogenic phenotype, carbapenem resistance caused by the presence of a carbapenemase is readily diagnosed by whole genome sequencing or even simple PCR-based genome tests.</p><p>It has recently become apparent that numerous CRE infections do not depend on the expression of carbapenemases, and there is mounting evidence that these non-carbapenemase CRE are widespread (<xref ref-type="bibr" rid="bib8">Bouganim et al., 2020</xref>). Based on the limited cases identified for non-carbapenemase CRE so far, it has been suggested that they emerge because of reduced outer membrane permeability and/or increased drug efflux (<xref ref-type="bibr" rid="bib48">Logan and Weinstein, 2017</xref>; <xref ref-type="bibr" rid="bib30">Goodman et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Tamma et al., 2017a</xref>). Other studies have suggested that, at least in some genetic backgrounds, an extended-spectrum β-lactamase (ESBL) could provide sufficient activity against carbapenems as to generate a CRE phenotype (<xref ref-type="bibr" rid="bib17">Codjoe and Donkor, 2017</xref>; <xref ref-type="bibr" rid="bib33">Halat et al., 2016</xref>). Despite this emerging knowledge, few studies have directly demonstrated the cause of non-carbapenemase CRE, and the evolutionary forces that shape the evolution of this trait have not been addressed. Understanding the details of these evolutionary forces could provide a means to re-sensitise populations of bacteria to carbapenems.</p><p>A patient died as a result of septicaemia caused by a <italic>Klebsiella</italic> isolate, FK688, where the infection did not respond to treatment with carbapenems (<xref ref-type="bibr" rid="bib5">Bi et al., 2017</xref>). In this study, we present the complete genome sequence of <italic>Klebsiella</italic> FK688, using a compilation of short- and long-read sequence data (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We identify, and experimentally confirm the genetic basis of the non-carbapenemase CRE phenotype in FK688: carriage of a mega-plasmid (pNAR1) and an inactivating mutation in the chromosomal gene <italic>ompK36</italic>. We show that non-carbapenemase CRE strains are unfit and readily evolve to be drug-sensitive in the absence of carbapenem antibiotics. The evolution of these low-fitness CRE strains may be contingent on their recent exposure to antibiotics that select for other β-lactamases which may explain the evolution of non-carbepenemase CRE.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Experiment overview.</title><p>(<bold>A</bold>) Carbapenem-resistant <italic>Klebsiella</italic> spp. were isolated from a patient, and the genome was sequenced and assembled. The genetic cause of resistance was confirmed by re-engineering the carbapenem resistance, partly based on structure guided restoration of a partially truncated membrane protein. The evolutionary drivers of resistance and sensitivity were determined using experimental evolution and extensive phenotypic and genotypic measures of evolutionary change. (<bold>B</bold>) Maximum likelihood phylogenetic tree of 377 publicly available <italic>Klebsiella</italic> genomes shows <italic>K. pneumoniae</italic> and <italic>K. quasipneumoniae</italic> as distinct species. The inner ring colours refer to the country of isolation according to the key, and further data is described in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. (<bold>C</bold>) Eight candidate carbapenemases were identified in the FK688 genome sequence and overexpressed in an <italic>E. coli</italic> model of resistance. Only two enzymes (DHA1 and OKP-B-21) conferred resistance to the cephem antibiotics tested, and none of the enzymes conferred resistance to the carbapenem antibiotics (<xref ref-type="supplementary-material" rid="fig1sdata6">Figure 1—source data 6</xref> and <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Strain information for <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Growth rate analysis of <italic>Escherichia coli</italic> BW25113 strains expressing the indicated open-reading frames cloned into plasmid pJP-CmR.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig1-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Antibiotic resistance genes identified in pNAR1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig1-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>Transmembrane transporter systems identified in pNAR1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig1-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>β-lactamase prediction and classification using DeepBL.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig1-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata6"><label>Figure 1—source data 6.</label><caption><title>Minimum inhibitory concentration (MIC) analysis of <italic>Escherichia coli</italic> BW25113 expressing DeepBL candidates and MIC analysis of FK688 pNAR1ΔblaDHA-1 strains expressing DHA-1.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig1-data6-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Physical map of the <italic>K. quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> FK688 chromosome.</title><p>The position of genes encoding antibiotic resistance determinants (<italic>oqxAB</italic>, <italic>bla</italic><sub>OKP-B-21</sub>, <italic>kdeA</italic>, and <italic>fosA5</italic>) and major outer membrane porin proteins (<italic>ompK35</italic>, <italic>ompK36</italic>, <italic>ompK37</italic>, and <italic>ompK38</italic>) are indicated. The blue lines in the two outer concentric circles represent the location of predicted coding sequences in the forward (outermost) and reverse DNA strands. The middle circle (black) indicates the % Guanine-Cytosine (GC) content, and the inner circle indicates the positive (green) and negative (purple) GC skew ([G−C]/[G+C]). The map was generated with DNAPlotter (<xref ref-type="bibr" rid="bib13">Carver et al., 2009</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>The phylogeny of <italic>Klebsiella</italic>.</title><p>Maximum likelihood phylogenetic tree of 377 publicly available <italic>Klebsiella</italic> genomes shows <italic>K. pneumoniae</italic> and <italic>K. quasipneumoniae</italic> as distinct species. The inner ring indicates the country of strain isolation, as specified in the colour key (NA, not applicable, indicates the genomes with location not deposited in the NCBI). The middle and outer ring colours indicate the distribution of the sequence type classifications with the ST number and colour key, respectively (ST, sequence type; SLV, single-locus variant; 2LV, two-locus variant). The position of strain FK688 is shown.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Domain architecture of DeepBL candidates.</title><p>(<bold>A</bold>) The Conserved Domain Architecture Retrieval Tool (CDART; <xref ref-type="bibr" rid="bib28">Geer et al., 2002</xref>) was used to create the graphical display of domain architectures for the protein sequences identified from DeepBL analysis of the FK688 genome sequence data (<xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). DHA-1, OPK-B-21, and several other of the open-reading frames show protein architecture of the Class C β-lactamase (green). TRN, ABH, and OPHC have a domain architecture similar to Serine-tRNA deacylase (blue), Alpha/Beta fold hydrolase (yellow), and Metallo-hydrolase-like_MBL-fold superfamily (orange), respectively. Numbers map the amino acid residues for each protein. (<bold>B</bold>) Growth rate analysis of <italic>E. coli</italic> BW25113 strains expressing the indicated open-reading frames cloned into plasmid pJP-CmR (<xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). In each case, the comparison is made between untransformed BW25113 (“no vector”, green triangles), and BW25113 transformed with the parental plasmid (“pJP-CmR”, red squares) or the plasmid carrying the indicated open-reading frame (blue dots). Strains were cultured in Lysogeny Broth (LB) for 24 hr at 37°C, and cell density (OD<sub>600</sub>) was measured every hour. Error bars represent the SD of biological triplicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig1-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>Klebsiella</italic> FK688 does not encode a carbapenemase</title><p>First, to determine the genetic basis of carbapenem resistance in FK688 (<xref ref-type="table" rid="table1">Table 1</xref>), we used a long- and short-read sequencing approach to generate a complete assembly of the FK688 genome (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The genome assembly revealed a circular chromosome (5,211,811 bp) and a novel circular megaplasmid (pNAR; 1,257,585 bp). This plasmid carried many antibiotic resistance genes corresponding to the known resistance profile (<xref ref-type="bibr" rid="bib5">Bi et al., 2017</xref>), as well as genes encoding efflux pumps and other transporters (<xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>, <xref ref-type="supplementary-material" rid="fig1sdata4">Figure 1-source data 4</xref>). Phylogenetic analysis placed FK688 within <italic>K. quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Readily identifiable determinants of AMR on the FK688 chromosome are a <italic>bla</italic><sub>OKP-B-21</sub> gene encoding a β-lactamase that confers resistance to penicillins and cephalosporins such as cefazolin, as well as determinants for quinolone (<italic>oqxA</italic>, <italic>oqxB</italic>; <xref ref-type="bibr" rid="bib10">Brisse et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Mathers et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Rodrigues et al., 2019</xref>) and fosfomycin (<italic>fosA5</italic>) resistance (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Antimicrobial susceptibility profiling of <italic>K. quasipneumoniae</italic> FK688.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Antimicrobial</th><th align="left" valign="bottom">Antimicrobial</th><th align="center" valign="bottom" colspan="3">MIC (µg/mL)<xref ref-type="table-fn" rid="table1fn1">*</xref></th></tr><tr><th align="left" valign="bottom">Class</th><th align="left" valign="bottom">Drug</th><th align="center" valign="bottom">FK688</th><th align="center" valign="bottom"><italic>E. coli</italic> (ATCC 25922)</th><th align="center" valign="bottom">Breakpoints<xref ref-type="table-fn" rid="table1fn2"><sup>†</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="bottom">Penicillins</td><td align="left" valign="bottom">Ampicillin</td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><italic>8</italic></td><td align="center" valign="bottom">≥32</td></tr><tr><td align="left" valign="bottom">Cephems</td><td align="left" valign="bottom">Cefazolin</td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom">≥8</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Cefotaxime</td><td align="center" valign="bottom"><bold>1024</bold></td><td align="center" valign="bottom"><italic>0.125</italic></td><td align="center" valign="bottom">≥4</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Ceftazidime</td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom">≥16</td></tr><tr><td align="left" valign="bottom">Carbapenems</td><td align="left" valign="bottom">Ertapenem</td><td align="center" valign="bottom"><bold>64</bold></td><td align="center" valign="bottom"><italic>0.016</italic></td><td align="center" valign="bottom">≥2</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Imipenem</td><td align="center" valign="bottom"><bold>8</bold></td><td align="center" valign="bottom"><italic>0.25</italic></td><td align="center" valign="bottom">≥4</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Meropenem</td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><italic>0.03</italic></td><td align="center" valign="bottom">≥4</td></tr><tr><td align="left" valign="bottom">Lipopeptides</td><td align="left" valign="bottom">Polymyxin B</td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom">≥4</td></tr><tr><td align="left" valign="bottom">Aminoglycosides</td><td align="left" valign="bottom">Gentamicin</td><td align="center" valign="bottom"><italic>1</italic></td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom">≥16</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Tobramycin</td><td align="center" valign="bottom"><italic>1</italic></td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom">≥16</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Kanamycin</td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom"><italic>4</italic></td><td align="center" valign="bottom">≥64</td></tr><tr><td align="left" valign="bottom">Tetracyclines</td><td align="left" valign="bottom">Tetracycline</td><td align="center" valign="bottom"><bold>128</bold></td><td align="center" valign="bottom"><italic>1</italic></td><td align="center" valign="bottom">≥16</td></tr><tr><td align="left" valign="bottom">Fluoroquinolones</td><td align="left" valign="bottom">Ciprofloxacin</td><td align="center" valign="bottom"><bold>1</bold></td><td align="center" valign="bottom"><italic>0.016</italic></td><td align="center" valign="bottom">≥1</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>Drug-sensitive, <italic>italics</italic>; drug-resistant, <bold>bold</bold>-text.</p></fn><fn id="table1fn2"><label>†</label><p>Resistant clinical breakpoint for <italic>Enterobacterales</italic> given by <xref ref-type="bibr" rid="bib16">CLSI, 2022</xref>.</p></fn></table-wrap-foot></table-wrap><p>Our genome sequence analysis did not reveal a gene encoding KPC-2, the carbapenemase found in many <italic>K. quasipneumoniae</italic> isolates (<xref ref-type="bibr" rid="bib54">Mathers et al., 2019</xref>). To identify any cryptic carbapenemases that may have escaped annotation, we made use of the machine learning predictor DeepBL (<xref ref-type="bibr" rid="bib84">Wang et al., 2021</xref>). DeepBL identifies genes encoding β-lactamases of all types, including carbapenemases, and generated eight high-confidence predictions. The two highest predictions represent known β-lactamases <italic>bla</italic><sub>OKP-B-21</sub> and <italic>bla</italic><sub>DHA-1</sub>. The next closest predictions were for proteins annotated as “serine hydrolase” (SHK), “MBL fold-metallo hydrolase” (OPHC), and “<sub>D</sub>-alanyl-<sub>D</sub>-alanine endopeptidase” (DAE) with conserved domain architecture retrieval tool predictions, suggesting that our search was sufficiently broad to identify plausible candidates (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). To test for carbapenemase activity, we expressed each of the eight genes in <italic>Escherichia coli</italic> and measured growth (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>, <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). Minimum inhibitory concentration (MIC) assays of <italic>E. coli</italic> expressing the DeepBL candidates showed that only OKP-B-21 and DHA-1 have β-lactamase activity that includes significant resistance to ceftazidime, a third-generation cephalosporin (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="fig1sdata6">Figure 1—source data 6</xref>). However, neither OKP-B-21 nor DHA-1 - nor any of the other proteins tested - provided resistance to carbapenems. Taken together with the genome sequence analysis, these data support that the observed carbapenem-resistant phenotype for FK688 is not caused by a carbapenemase.</p></sec><sec id="s2-2"><title>The major porins permit carbapenem sensitivity in <italic>K. quasipneumoniae</italic></title><p>Porins are β-barrel proteins that transport nutrients across the outer membrane of Gram-negative bacteria but can also admit antibiotics into the bacterial cell (<xref ref-type="bibr" rid="bib51">Martínez-Martínez et al., 1996</xref>; <xref ref-type="bibr" rid="bib58">Nicolas-Chanoine et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref>). <italic>K. pneumoniae</italic> has four genes encoding the major porins OmpK35, OmpK36, OmpK37, and OmpK38 (<xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref>), and the position and synteny of each gene in FK688 are conserved across <italic>K. quasipneumoniae</italic> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Inspection of the predicted protein sequences encoded by the four genes in FK688 revealed a 1.3 kb transposase gene (IS<italic>4</italic> family) insertion within the 5’ end of the <italic>ompK35</italic> gene (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>) and a 48 bp in-frame deletion in <italic>ompK36</italic> in FK688 (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>The structure of OmpK36 (PDB 5O79) is known (<xref ref-type="bibr" rid="bib1">Acosta-Gutiérrez et al., 2018</xref>), and the identified deletion of 16 amino acids at the 3’ end of the <italic>ompK36</italic> gene in FK688 encompasses large portions of the β14 and β15 strands of the β-barrel structure (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2">Figure 2B</xref>), explaining why the protein is not assembled into the outer membrane of FK688. To confirm that this mutation was contributing to carbapenem resistance, we used the ompK36 gene from <italic>K. quasipneumoniae subsp.</italic> similipneumoniae ATCC 700603 (<xref ref-type="bibr" rid="bib24">Elliott et al., 2016</xref>) to carry out structure-informed repair of the OmpK36 gene in <italic>K. quasipneumoniae</italic> FK688 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>)<italic>.</italic> The resultant strain (<italic>ompK36</italic><sup>+</sup> pNAR1) was subjected to immunoblotting with antisera, confirming the restoration of OmpK36 expression in the <italic>ompK36</italic><sup>+</sup> pNAR1 strain (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref> and <xref ref-type="supplementary-material" rid="fig2sdata2">Figure 2—source data 2</xref>). Finally, measurements of carbapenem MIC determined that the repaired gene encoding the porin OmpK36 restored carbapenem sensitivity (<xref ref-type="table" rid="table2">Table 2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Reconstruction of mutant OmpK36 protein based structural characteristics of OmpK36 in <italic>K.</italic> <italic>quasipneumoniae</italic> subsp<italic>. similipneumoniae</italic>.</title><p>(<bold>A</bold>) PSIPRED (<xref ref-type="bibr" rid="bib11">Buchan and Jones, 2019</xref>) secondary structure prediction of the OmpK36, using the protein sequence encoded in the <italic>K. quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> genome. The location of the 16 amino acid deleted region in FK688 OmpK36 is highlighted in red on the β14-β15 strands of the corresponding structural model. (<bold>B</bold>) Tertiary structure of the β-barrel OmpK36 monomer (PDB ID 5O79 <xref ref-type="bibr" rid="bib1">Acosta-Gutiérrez et al., 2018</xref>). Coloured red are the β14-β15 strands, the same region designated with red colour in panel (<bold>A</bold>). (<bold>C</bold>) Schematic depicting the engineering to restore a functional version of <italic>ompK36</italic> in FK688 by the insertion of 48 nucleotides in <italic>ompK36</italic>, as shown in red. FRT (flippase recognition target) sites permitted excision of the Km<sup>R</sup> (kanamycin resistance) cassette using Flp recombinase. Following Km<sup>R</sup> excision, a single FRT site and scar region remain in between the <italic>ompK36</italic> and <italic>apbE</italic> genes. The amino acid identity between the OmpK36 from ATCC 700603 and FK688 is 95% (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>), and the ATCC 700603 sequence (<xref ref-type="bibr" rid="bib24">Elliott et al., 2016</xref>) was used to repair the <italic>ompK36</italic> locus of FK688, as described in the Materials and methods section. (<bold>D</bold>) Total membrane extracts were prepared from the indicated strains, the proteins in the samples analysed by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and immunoblotting using an antibody probe that recognises OmpK36 (<xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref>). The outer-membrane protein BamD was used as a sample loading control for the analysis.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original gel image for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83107-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Alternative gel image for <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83107-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Gene alignment of four major porins.</title><p>Gene synteny comparison alignments of <italic>ompK35</italic>, <italic>ompK36</italic>, <italic>ompK37</italic>, and <italic>ompK38</italic> (green arrows) and neighbouring open reading frames (ORFs) with either predicted (purple arrows) or unknown (grey arrows) functions in FK688 and <italic>K. pneumoniae</italic> subsp. <italic>pneumoniae</italic> ATCC 43816 reference strain. Comparisons were created with BLASTn and the Easyfig application (<xref ref-type="bibr" rid="bib81">Sullivan et al., 2011</xref>) using the default parameters (min. length = 0, max. e value = 0.001, and min. identity value = 0). The red line was drawn to indicate the position of a 48 bp intragenic region within <italic>ompK36</italic> present in ATCC 43816 and absent in FK688, which was not detected at the level of resolution used in BLASTn comparative analysis. The nucleotide sequence percentage identity between strains is represented by the gradient indicator (bottom left).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Comparative sequence analysis of <italic>ompK35</italic> and <italic>ompK36</italic> genes of <italic>Klebsiella</italic> spp. and reference genomes.</title><p>(<bold>A</bold>) BLAST searches of sequence data held at NCBI did not identify any other <italic>Klebsiella</italic> strains carrying a <italic>tnpA</italic> insertion in the 5’ end of <italic>ompK35.</italic> However, such an insertion is seen in <italic>E. coli</italic> 1290/03 which has a <italic>tnpA</italic> inserted 45 bp upstream of the start codon of the <italic>ompK35</italic> homolog (<italic>ompF</italic>). A non-identical but similar <italic>tnpA</italic> insertion is seen 42 bp upstream of the start codon of the <italic>ompK36</italic> gene of <italic>K. pneumoniae</italic> WJ19, and 45 bp upstream of the start codon of the <italic>ompK36</italic> homolog (<italic>ompC</italic>) in <italic>E. coli</italic> strains 1290/03, 917/05, and 1566/03. Alternate means disrupting the functionality of the porin encoding genes were also observed with SNPs that generate premature stop codons indicated by red lines. GenBank accession numbers of the sequences are as follows: <italic>E. coli</italic> 1290/03, GQ465829; <italic>K. pneumoniae</italic> WJ19, Q4557043; <italic>E. coli</italic> 917/05, GQ167039; <italic>E. coli</italic> 1566/03, GQ167038. Sequence comparisons were created with ViPTree (<xref ref-type="bibr" rid="bib59">Nishimura et al., 2017</xref>). (<bold>B</bold>) OmpK36 amino acid sequences from FK688, other <italic>K. quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> (Kqs) strains and a <italic>K. pneumoniae</italic> strain (Kpn) extracted from the NCBI database. The conceptual translation of the OmpK36 encoded by the Kpn KP549/04 strain (<xref ref-type="bibr" rid="bib88">Wu et al., 2011</xref>) had the same 16-amino acid deletion as FK688 (blue box). Residues showing 100% identity among sequences are highlighted in red. Similarity among sequences is indicated by black bold font highlighted in yellow. Accession numbers for the proteins shown are as follows: UNMC_7493: OVT66776.1; G1129: OVX13856.1; KP-24175: KYZ7217.4; CAB1577: OVX38519.1; KPPSTH03: OYM42369.1; KPCTRSRTH03: TNJ78288.1; ATCC 700603: AWO62949.1; MGH44: ESM62951.1; SWT10: TWV32269.1; KP549/04: ADG56566.1; SB610: VGP86012.1; G747: AZJ27052.1. Sequence alignments were performed with Clustal Omega (<xref ref-type="bibr" rid="bib50">Madeira et al., 2019</xref>) and rendered with ESPript 3.0 (<xref ref-type="bibr" rid="bib11">Buchan and Jones, 2019</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig2-figsupp2-v1.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Antimicrobial susceptibility profiling of FK688-derived strains.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="3">Antimicrobial Class</th><th align="left" valign="bottom" rowspan="3">AntimicrobialDrug</th><th align="center" valign="bottom" colspan="5">MIC (µg/mL)<xref ref-type="table-fn" rid="table2fn1">*</xref></th></tr><tr><th align="center" valign="bottom" colspan="3">Δ<italic>ompK36</italic></th><th align="center" valign="bottom" colspan="2"><italic>ompK36</italic><sup>+</sup></th></tr><tr><th align="center" valign="bottom">pNAR1</th><th align="center" valign="bottom">pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></th><th align="center" valign="bottom">pNAR1<sup>−</sup></th><th align="center" valign="bottom">pNAR1</th><th align="center" valign="bottom">pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></th></tr></thead><tbody><tr><td align="left" valign="bottom">Penicillins</td><td align="left" valign="bottom">Ampicillin</td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><bold>256</bold></td><td align="center" valign="bottom"><bold>128</bold></td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><bold>128</bold></td></tr><tr><td align="left" valign="bottom">Cephems</td><td align="left" valign="bottom">Cefazolin</td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><bold>32</bold></td><td align="center" valign="bottom"><bold>32</bold></td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><italic>4</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Cefotaxime</td><td align="center" valign="bottom"><bold>1024</bold></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom"><bold>32</bold></td><td align="center" valign="bottom"><italic>0.125</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Ceftazidime</td><td align="center" valign="bottom"><bold>&gt;2048</bold></td><td align="center" valign="bottom"><italic>1</italic></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom"><bold>512</bold></td><td align="center" valign="bottom"><italic>0.25</italic></td></tr><tr><td align="left" valign="bottom">Carbapenems</td><td align="left" valign="bottom">Ertapenem</td><td align="center" valign="bottom"><bold>64</bold></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom"><italic>0.5</italic></td><td align="center" valign="bottom"><italic>0.016</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Imipenem</td><td align="center" valign="bottom"><bold>8</bold></td><td align="center" valign="bottom"><italic>0.25</italic></td><td align="center" valign="bottom"><italic>0.25</italic></td><td align="center" valign="bottom"><italic>1</italic></td><td align="center" valign="bottom"><italic>0.12</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Meropenem</td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><italic>0.06</italic></td><td align="center" valign="bottom"><italic>0.125</italic></td><td align="center" valign="bottom"><italic>0.125</italic></td><td align="center" valign="bottom"><italic>0.03</italic></td></tr><tr><td align="left" valign="bottom">Lipopeptides</td><td align="left" valign="bottom">Polymyxin B</td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><bold>4</bold></td><td align="center" valign="bottom"><bold>4</bold></td></tr><tr><td align="left" valign="bottom">Aminoglycosides</td><td align="left" valign="bottom">Kanamycin</td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom"><italic>4</italic></td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom"><italic>4</italic></td><td align="center" valign="bottom"><italic>4</italic></td></tr><tr><td align="left" valign="bottom">Tetracyclines</td><td align="left" valign="bottom">Tetracycline</td><td align="center" valign="bottom"><bold>128</bold></td><td align="center" valign="bottom"><bold>256</bold></td><td align="center" valign="bottom"><italic>2</italic></td><td align="center" valign="bottom"><bold>128</bold></td><td align="center" valign="bottom"><bold>128</bold></td></tr><tr><td align="left" valign="bottom">Fluoroquinolones</td><td align="left" valign="bottom">Ciprofloxacin</td><td align="center" valign="bottom"><bold>1</bold></td><td align="center" valign="bottom"><italic>0.06</italic></td><td align="center" valign="bottom"><italic>0.06</italic></td><td align="center" valign="bottom"><bold>1</bold></td><td align="center" valign="bottom">0.125</td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>Drug-sensitive, <italic>italics</italic>; drug-resistant, <bold>bold</bold>-text.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3"><title>DHA-1 and Δ<italic>ompK36</italic> are required for carbapenem resistance and impose non-additive fitness costs in growth media without antibiotics</title><p>To determine the evolutionary stability of the pNAR1 plasmid, we passaged 10 replicate mutation accumulation lines of <italic>K. quasipneumoniae</italic> FK688 in growth media without β-lactam antibiotic selection (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). After 11 passages, two replicates had completely lost resistance to the β-lactam antibiotic ceftazidime. The first lineage lost a 17 kb region of pNAR1 that included the <italic>bla</italic><sub>DHA-1</sub> and <italic>qnrB4</italic> antibiotic resistance genes flanked by the gene mobility elements <italic>tnpA-sul1</italic> (pNAR1Δ<italic>bla</italic><sub>DHA-1</sub>) while the second lineage lost the entire pNAR1 plasmid (pNAR1‾; <xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3">Figure 3C</xref>). We assayed both the pNAR1‾ and pNAR1Δ<italic>bla</italic><sub>DHA-1</sub> strains for growth (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>) and antibiotic sensitivity (<xref ref-type="table" rid="table2">Table 2</xref>) and confirmed that loss of pNAR1, and specifically the <italic>tnpA-sul1</italic> region of pNAR1, caused a loss of resistance to ceftazidime and carbapenem.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Evolution and physical map of plasmid pNAR1.</title><p>(<bold>A</bold>) Schematic representation of the in vitro evolution experiment. After passage #3 (P3), a ceftazidime-susceptible (CAZ<sup>S</sup>) mutant evolved, lacking a 17 kb region of pNAR1 that included <italic>bla</italic><sub>DHA-1</sub> (referred to as Δ<italic>ompK36</italic> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub>). After 11 passages (P11) a CAZ<sup>S</sup> colony missing the entire plasmid (referred to as Δ<italic>ompK36</italic> pNAR1¯) evolved. In total, 20 passages were performed, and another five CAZ<sup>S</sup> colonies were identified, each missing the 17 kb region of pNAR1 that includes <italic>bla</italic><sub>DHA-1</sub>. (<bold>B</bold>) The position of genes encoding antibiotic resistance determinants (red), and efflux pumps annotated as being for mercury resistance (green), copper resistance (orange), and silver resistance (pink) are indicated. In addition to <italic>bla</italic><sub>DHA-1</sub>, pNAR1 carries genes encoding AmpR (ID00077) a transcriptional regulator known to regulate expression of <italic>bla</italic><sub>DHA-1</sub> (<xref ref-type="bibr" rid="bib67">Realegeno et al., 2021</xref>). Also, other drug resistance genes including those responsible for resistance to tetracycline (<italic>tetA</italic>[B]), rifamycin (<italic>arr-3</italic>), trimethoprim (<italic>dfrA27</italic>), streptomycin (<italic>aadA16</italic>), macrolides (<italic>qacΔE1</italic>), sulfonamides (<italic>sul1</italic>), and quinolones and fluoroquinolones (<italic>qnrB4</italic>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig1sdata3">Figure 1—source data 3</xref>). The location of predicted coding sequences in the forward (outer most) and reverse DNA strands is designated by purple boxes in the outer concentric circles. The middle circle (black) graphs the % GC content, and the inner circle indicates the positive (green) and negative (purple) GC skew ([G−C]/[G+C]). The map was generated with DNAPlotter (<xref ref-type="bibr" rid="bib13">Carver et al., 2009</xref>). The black arc designates a 41 kb segment of DNA expanded in panel C. (<bold>C</bold>) Linear map of the 41 kb segment of pNAR1 showing the genetic arrangement of antimicrobial resistance genes (red), mobile genetic elements (blue), annotated coding sequences (purple), and hypothetical genes of unknown function (grey). Assigned IS families are shown underneath each transposase gene (<italic>tnpA</italic>). The loci within the two brackets represent the 17 kb DNA segment (<italic>tnpA-sul1</italic>) deleted from pNAR1Δ<italic>bla</italic><sub>DHA-1</sub>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Growth rate analysis of <italic>K.</italic> <italic>quasipneumoniae</italic> strains.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Detailed physical map of the FK688 plasmid pNAR1.</title><p>The coloured lines in the outer concentric circles represent the location of predicted coding sequences in the forward and reverse DNA strands. Annotated CoDing Sequences (CDS) are shown in dark blue and labelled with gene names. Hypothetical genes of unknown function are in grey. Mobile genetic elements are in light blue. The position of genes encoding antibiotic resistance determinants (red), mercury (<italic>mer</italic>) resistance (green), copper (<italic>pco</italic>) resistance (orange), and silver (<italic>sil</italic>) resistance (pink) is indicated. The genes encoding a Fe (3+) dicitrate ABC transporter system are in dark brown. The Type 1 <italic>hsdRMS</italic> restriction-modification and H-N-H endonuclease (<italic>hnh</italic>) systems (yellow) and phage shock protein (Psp) system (light brown) are indicated. The middle circle (black) indicates the % GC content, and the inner circle indicates the positive (green) and negative (purple) GC skew ([G−C]/[G+C]). The map was generated with DNAPlotter (<xref ref-type="bibr" rid="bib13">Carver et al., 2009</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Growth rate analysis of <italic>K. quasipneumoniae</italic> strains.</title><p>Bacteria was cultured in cation-adjusted Mueller-Hinton Broth (CAMHB), and the OD<sub>600</sub> was measured every hour for 24 hr. Error bars represent SD (n=3). The genotypes of the strains are indicated in the legend. Note that the parental FK688 strain is Δo<italic>mpK36</italic> pNAR1. Where indicated, the other isogenic strains express a functional OmpK36 porin (i.e. <italic>ompK36</italic><sup>+</sup>), carry the complete pNAR1 plasmid or pNAR1 with a 17 kb (<italic>tnpA-sul1</italic>) deletion (pNAR1<italic>Δbla</italic><sub>DHA-1</sub>), or have been cured of the plasmid (pNAR1¯).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig3-figsupp2-v1.tif"/></fig></fig-group><p>Whole genome sequencing established that the pNAR1‾ and pNAR1Δ<italic>bla</italic><sub>DHA-1</sub> strains had not sustained any other mutations, which confirmed the genotypes of strains Δ<italic>ompK36 and ompK36<sup>+</sup></italic> with and without the plasmid-encoded <italic>bla</italic><sub>DHA-1</sub><italic>gene.</italic> We therefore engineered repaired versions <italic>ompK36<sup>+</sup></italic> for each strain and tested each mutant for growth and carbapenem resistance (<xref ref-type="table" rid="table2">Table 2</xref>). The results demonstrate that the acquisition of carbapenem-resistance in FK688 required the combination of (i) the absence of porins and (ii) the β-lactamase DHA-1 (<xref ref-type="supplementary-material" rid="fig1sdata6">Figure 1—source data 6</xref>).</p><p>While the expression of DHA-1 and the absence of a functional porin provides a selective advantage to <italic>Klebsiella</italic> in high concentrations of carbapenem antibiotics, we sought to understand whether these genotypes impose a fitness cost in environments without carbapenems. Competitive fitness assays were carried out to determine the fitness effects of the <italic>bla</italic><sub>DHA-1</sub> and <italic>ompK36</italic> alleles alone and in combination (Materials and methods, <xref ref-type="fig" rid="fig4">Figure 4A</xref>). We found that the <italic>bla</italic><sub>DHA-1</sub> and <italic>ΔompK36</italic> alleles conferred a substantial fitness cost in growth media without antibiotic as compared to the other strains tested (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). To refine our understanding in terms of carbapenem-resistance, we measured the fitness effects of the <italic>bla</italic><sub>DHA-1</sub> and <italic>ompK36</italic> alleles across a range of imipenem concentrations. These assays showed that the fitness defects seen in the absence of imipenem (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) are gradually reversed in the strains grown in the presence of increasing concentrations imipenem (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>). At the breakpoint value of 0.125 µg/mL, three genotypes are already at a selective disadvantage: <italic>ompK36<sup>+</sup></italic>pNAR1Δ<italic>bla</italic><sub>DHA-1</sub>, <italic>ompK36<sup>+</sup></italic>pNAR1, and Δ<italic>ompK36</italic> pNAR1<italic>‾.</italic> Above the breakpoint value at 0.25 µg/mL, all four genotypes are at a selective disadvantage relative to the parental FK688. Thus, a clinically relevant appearance of the CRE phenotype requires a combination of the presence of DHA-1 and the lack of a functional porin.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Competitive fitness assay of FK688 strain variants against GFP-labelled FK688.</title><p>(<bold>A</bold>) Schematic of the competitive fitness assay experiment (Materials and methods). FACS: fluorescence-activated cell sorting. (<bold>B</bold>) The relative fitness of the engineered mutant strains relative to the carbapenem resistant FK688 strain, measured in Lysogeny Broth (LB) growth media without antibiotics. Mutant strains either have the OmpK36 outer membrane transporter restored (<italic>ompK36<sup>+</sup></italic>), the DHA-1 β-lactamase deleted (pNAR1¯ or pNAR1Δ<italic>bla</italic><sub>DHA-1</sub>), or both (orange circles). The y-axis shows the selection coefficient (S) per generation compared to the carbapenem resistant ancestor FK688 which has its fitness set at 0. The legend indicates the genotypes for each strain (note FK688 is genotype Δ<italic>ompK36</italic> pNAR1). Error bars represent mean ± SD (n=4). (<bold>C</bold>) Relative fitness of FK688 mutant strains compared to parental FK688, measured in LB media supplemented increasing concentrations of the carbapenem antibiotic imipenem. The legend shows the genotype for each <italic>Klebsiella</italic> strain. Error bars represent mean ± SD (n=4).</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Relative fitness values for each data point in <xref ref-type="fig" rid="fig4">Figure 4B and C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig4-v1.tif"/></fig></sec><sec id="s2-4"><title>High fitness and carbapenemase sensitivity rapidly evolve in experimental populations of FK688</title><p>Mutations that inactivate major porins restrict the permeability of the outer membrane. To address the fitness cost of major porin loss over time, we passaged 20 Δ<italic>ompK36</italic> pNAR1 (lineage A) and 20 <italic>ompK36</italic><sup>+</sup> pNAR1 (lineage B) replicate populations across 200 generations of evolution in media without antibiotics (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The ancestral FK688 strains (Δ<italic>ompK36</italic> pNAR1 and <italic>ompK36</italic><sup>+</sup> pNAR1) have an opaque colony morphology. This is consistent with a phenotype of capsular polysaccharide production: non-fimbriated <italic>Klebsiella</italic> strains are mucoid due to capsule secretion and look opaque, while translucent colonies are fimbriated and non-mucoid (<xref ref-type="bibr" rid="bib53">Matatov et al., 1999</xref>; <xref ref-type="bibr" rid="bib74">Schembri et al., 2005</xref>; <xref ref-type="bibr" rid="bib86">Wilksch et al., 2011</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Genotypic and phenotypic evolution of FK688 Δ<italic>ompK36</italic> and <italic>ompK36<sup>+</sup></italic>strains.</title><p>(<bold>A</bold>) Schematic of the evolution experiment of Lineage A (FK688:Δ<italic>ompK36</italic> pNAR1) and Lineage B (FK688:<italic>ompK36<sup>+</sup></italic>pNAR1). 20 replicate populations (A1, A2, A3,…A20 and B1, B2, B3,…B20) for each lineage were serially passaged (1000-fold dilutions at each passage) for 200 generations. Of the evolved strains, population A2 and population B3 were characterised as described in the text. While population A2 showed a mixture of both opaque (o) and translucent (t) colony morphotypes, the asterisk (*) denotes that only a single colony of opaque (o) morphotype was observed in population B3. (<bold>B</bold>) Colony morphotypes seen in the evolved populations. Colonies were grown on 0.5✕ Lysogeny Broth (LB) agar for an overnight incubation at 37°C and photographed with stereo microscope using transmitted light to capture translucency. (<bold>C</bold>) The relative fitness assessments for the populations of FK688 Δ<italic>ompK36</italic> pNAR1(pink) and populations of <italic>ompK36<sup>+</sup></italic>pNAR1 (blue) genotypes (left). The error bars represent mean ± SD (n=4). Relative fitness assays were also performed for 20 evolved populations after 200 generations of evolution in LB growth media without antibiotics (right). The line represents individual replicates with means connected. (<bold>D</bold>) Relative numbers of opaque colonies in the 20 replicate populations of FK688 Δ<italic>ompK36</italic> pNAR1 (lineage A) and <italic>ompK36<sup>+</sup></italic>pNAR1 (lineage B) strains after 200 generations. Each dot represents an individually evolved population. The inset photographs (above the graph) are an example of frequency of opaque and translucent colonies on an agar plate in one of the 20 replicate populations. (<bold>E</bold>) Capsular polysaccharide was extracted from cell cultures for glucuronic acid measurement (Materials and methods; <xref ref-type="bibr" rid="bib12">Campos et al., 2004</xref>). The error bars represent mean ± SD (n=3). For reference, ancestral and evolved strains were compared with the hypermucoid (i.e. heavily capsulated) clinical isolate B5055 and an isogenic mutant B5055nm Δ<italic>wza-wzc</italic> (non-mucoid) strain. (<bold>F</bold>) Total cell extracts from the indicated strains were analysed by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and Coomassie staining. The migration positions of OmpK36, PhoE, and OmpA are indicated. The identities of these protein species were confirmed by mass spectrometry of the corresponding region of the gel.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Fitness assay ancestral and evolved lineages A and B strains.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Relative numbers of opaque colonies in the 20 replicate populations of FK688 ΔompK36 pNAR1 (lineage A) and ompK36+pNAR1 (lineage B) strains after 200 generations.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig5-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>FK688 OmpK36+, B3(o), and B3(t) genome modification and SNP analysis.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig5-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Glucuronic acid measurement of ancestral and evolved strains.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig5-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Original gel image for <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83107-fig5-data5-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Comparative sequence analysis of the <italic>fim</italic> gene cluster in evolved <italic>K. quasipneumoniae</italic> strains.</title><p>Sequence comparison of FK688 <italic>ompK36</italic><sup>+</sup> revealed a tnpA gene from the IS<italic>4</italic> family (blue arrow) inserted upstream of <italic>fimE</italic> in B3(o). Sequence comparisons were performed with ViPTree (<xref ref-type="bibr" rid="bib59">Nishimura et al., 2017</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Comparative sequence analysis of the <italic>fim</italic> gene cluster in evolved <italic>K. quasipneumoniae</italic> strains.</title><p>Schematic of the FK688 and its evolved strains A2(o) and A2(t) <italic>fim</italic> gene cluster with 100% gene similarity between the strains. Sequence comparisons were performed with ViPTree (<xref ref-type="bibr" rid="bib59">Nishimura et al., 2017</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig5-figsupp2-v1.tif"/></fig></fig-group><p>The Δ<italic>ompK36</italic> pNAR1 (lineage A) populations evolved similar competitive fitness to the <italic>ompK36</italic><sup>+</sup> pNAR1 (lineage B) evolved populations, recovering the fitness cost of the Δ<italic>ompK36</italic> mutation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). To understand the molecular basis of these phenotypes, whole genome sequence data was analysed for four evolved strains: A2(o), A2(t), B3(o), and B3(t). Each, independently, sustained a deletion in pNAR1 that removed <italic>bla</italic><sub>DHA-1</sub>. This explains the increased carbapenem sensitivity of the Δ<italic>ompK36</italic> pNAR1 and <italic>ompK36</italic><sup>+</sup> pNAR1 lineages as they had now lost one of the genes contributing to provide the phenotype. After 200 generations of evolution, samples were plated on agar and were found to display a mixture of opaque and translucent colony morphotypes from each strain (<xref ref-type="fig" rid="fig5">Figure 5B</xref> and <xref ref-type="fig" rid="fig5">Figure 5D</xref>). This feature has been seen before in <italic>Klebsiella</italic> spp. and depends on the expression of type 1 fimbriae (<xref ref-type="bibr" rid="bib53">Matatov et al., 1999</xref>; <xref ref-type="bibr" rid="bib44">Klemm, 1986</xref>; <xref ref-type="bibr" rid="bib80">Struve et al., 2008</xref>).</p><p>The replicate population FK688 Δ<italic>ompK36</italic> pNAR1(A2) population evolved to become a mixture of opaque (o) and translucent (t) colony-forming types, and we chose one of each colony morphotype A2(o) and A2(t) for a more detailed analysis, while for the replicate population <italic>ompK36<sup>+</sup></italic> pNAR1 (B3) was almost entirely (594 of 595 colonies observed) made up of translucent colony-forming cells, we selected one of the translucent colonies B3(t) and recovered the only opaque colony B3(o) for further analysis (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, <xref ref-type="supplementary-material" rid="fig5sdata2">Figure 5—source data 2</xref>). In the single B3(o) isolate recovered, a transposase gene (IS<italic>4</italic> family) insertion had disrupted the downstream region of the <italic>fimE</italic> gene (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>, <xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>). The <italic>fimE</italic> gene was not disrupted in the A2 population that was capable of phase-switching (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Consistent with these observations, an assay measuring glucuronic acid that reflects the presence of capsule showed that the A2(o) and B3(o) had more capsular polysaccharide than A2(t) and B3(t) (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5—source data 4</xref>).</p><p>MIC analysis of the lineage A evolved strains showed that the Δ<italic>ompK36</italic> pNAR1 populations had evolved increased sensitivity to imipenem, 64-fold for the A2(o) and A2(t) strains, bringing them to the same MIC value as the B3(t) strain (<xref ref-type="table" rid="table3">Table 3</xref>). Protein analysis of A2(o) and A2(t) by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE; <xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="supplementary-material" rid="fig5sdata5">Figure 5—source data 5</xref>) and mass spectrometry showed no changes that were consistent in both populations to explain the increased sensitivity to imipenem. Our reconstruction experiments (<xref ref-type="table" rid="table2">Table 2</xref>) suggest that the primary determinant of this reversion of the AMR phenotype is the observed loss of the <italic>bla</italic><sub>DHA-1</sub> gene from the megaplasmid pNAR1.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Antimicrobial susceptibility profiling FK688 Δ<italic>ompK36</italic> and <italic>ompK36<sup>+</sup></italic> strains and their respective evolved strains.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="center" valign="bottom" colspan="6">MIC (µg/mL)<xref ref-type="table-fn" rid="table3fn1">*</xref></th></tr><tr><th align="left" valign="bottom">Antimicrobial</th><th align="left" valign="bottom">Antimicrobial</th><th align="center" valign="bottom" colspan="3">Δ<italic>ompK36</italic></th><th align="center" valign="bottom" colspan="3"><italic>ompK36</italic><sup>+</sup></th></tr><tr><th align="left" valign="bottom">Class</th><th align="left" valign="bottom">Drug</th><th align="left" valign="bottom">pNAR1</th><th align="left" valign="bottom">pNAR1 Δ<italic>bla</italic><sub>DHA-1</sub> A2(o)</th><th align="left" valign="bottom">pNAR1 Δ<italic>bla</italic><sub>DHA-1</sub>A2(t)</th><th align="left" valign="bottom">pNAR1</th><th align="left" valign="bottom">pNAR1 Δ<italic>bla</italic><sub>DHA-1</sub>B3(o)</th><th align="left" valign="bottom">pNAR1 Δ<italic>bla</italic><sub>DHA-1</sub> B3(t)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cephems</td><td align="left" valign="bottom">Cefazolin</td><td align="left" valign="bottom"><bold>&gt;2048</bold></td><td align="left" valign="bottom"><bold>32</bold></td><td align="left" valign="bottom">1</td><td align="left" valign="bottom"><bold>&gt;2048</bold></td><td align="left" valign="bottom"><italic>2</italic></td><td align="left" valign="bottom"><italic>1</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Cefotaxime</td><td align="left" valign="bottom"><bold>1024</bold></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.25</italic></td><td align="left" valign="bottom"><bold>32</bold></td><td align="left" valign="bottom"><italic>0.125</italic></td><td align="left" valign="bottom"><italic>0.25</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Ceftazidime</td><td align="left" valign="bottom"><bold>&gt;2048</bold></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.25</italic></td><td align="left" valign="bottom"><bold>512</bold></td><td align="left" valign="bottom"><italic>0.25</italic></td><td align="left" valign="bottom"><italic>0.25</italic></td></tr><tr><td align="left" valign="bottom">Carbapenems</td><td align="left" valign="bottom">Ertapenem</td><td align="left" valign="bottom"><bold>64</bold></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.031</italic></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.016</italic></td><td align="left" valign="bottom"><italic>0.031</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Imipenem</td><td align="left" valign="bottom"><bold>8</bold></td><td align="left" valign="bottom"><italic>0.125</italic></td><td align="left" valign="bottom"><italic>0.125</italic></td><td align="left" valign="bottom"><italic>1</italic></td><td align="left" valign="bottom"><italic>0.25</italic></td><td align="left" valign="bottom"><italic>0.125</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Meropenem</td><td align="left" valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><italic>0.125</italic></td><td align="left" valign="bottom"><italic>0.016</italic></td><td align="left" valign="bottom"><italic>0.12</italic></td><td align="left" valign="bottom"><italic>0.016</italic></td><td align="left" valign="bottom"><italic>0.016</italic></td></tr><tr><td align="left" valign="bottom">Tetracyclines</td><td align="left" valign="bottom">Tetracycline</td><td align="left" valign="bottom"><bold>128</bold></td><td align="left" valign="bottom"><bold>128</bold></td><td align="left" valign="bottom"><bold>128</bold></td><td align="left" valign="bottom"><bold>128</bold></td><td align="left" valign="bottom"><bold>128</bold></td><td align="left" valign="bottom"><bold>128</bold></td></tr><tr><td align="left" valign="bottom">Fluoroquinolones</td><td align="left" valign="bottom">Ciprofloxacin</td><td align="left" valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>0.125</italic></td><td align="left" valign="bottom"><italic>0.25</italic></td><td align="left" valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>0.031</italic></td><td align="left" valign="bottom"><italic>0.063</italic></td></tr><tr><td align="left" valign="bottom">Aminoglycosides</td><td align="left" valign="bottom">Kanamycin</td><td align="left" valign="bottom"><italic>2</italic></td><td align="left" valign="bottom"><italic>2</italic></td><td align="left" valign="bottom"><italic>2</italic></td><td align="left" valign="bottom"><italic>4</italic></td><td align="left" valign="bottom"><italic>2</italic></td><td align="left" valign="bottom"><italic>2</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Tobramycin</td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>1</italic></td><td align="left" valign="bottom"><italic>1</italic></td><td align="left" valign="bottom"><italic>1</italic></td><td align="left" valign="bottom"><italic>1</italic></td><td align="left" valign="bottom"><italic>1</italic></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">Gentamicin</td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>1</italic></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.5</italic></td><td align="left" valign="bottom"><italic>0.5</italic></td></tr><tr><td align="left" valign="bottom">Lipopeptides</td><td align="left" valign="bottom">Polymyxin B</td><td align="left" valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><bold>8</bold></td><td align="left" valign="bottom"><bold>4</bold></td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><label>*</label><p>Drug-sensitive, <italic>italics</italic>; drug-resistant, <bold>bold</bold>-text.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Non-carbapenemase carbapenem resistance evolves via ceftazidime resistance</title><p>The results so far confirm that two genetic variants are required for the evolution of non-carbapenemase resistance to imipenem. The evolution of this trait is puzzling because both the Δ<italic>ompK36</italic> strain and the <italic>bla</italic><sub>DHA-1</sub> positive strain each have a low fitness in growth media without antibiotic, as well as in growth media with imipenem. One explanation for the evolution of carbapenem resistance in a strain of <italic>Klebsiella</italic> with an intact major porin is the simultaneous acquisition of multiple genetic variations after the population was exposed to imipenem. However, given that the two genes are not linked, the simultaneous acquisition of a new gene (<italic>bla</italic><sub>DHA-1</sub>) and a spontaneous genetic variant (inactivating mutation in one or more major porins such as <italic>ompK36</italic>) is highly unlikely.</p><p>An alternative explanation is that the bacterial population may have first been subjected to environmental conditions that selected for the fixation of one of the alleles. For antibiotic resistance phenotypes, this is a realistic scenario. Given the difficulty with diagnosing a non-carbapenemase CRE infection, patients might first be treated with other β-lactams. To address this possibility, we tested whether an antibiotic other than imipenem could have selected for the presence of one or both alleles, thus potentiating the evolution of imipenem resistance with a single mutational step.</p><p>The fitness of each combination of the <italic>bla</italic><sub>DHA-1</sub> and <italic>ompK36</italic> alleles was tested in a range of ceftazidime concentrations (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, <xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>). This showed that <italic>bla</italic><sub>DHA-1</sub> was selectively favoured, even at concentrations of ceftazidime approximately 100× below the clinical breakpoint of 16 µg/mL, despite the fact that carriage of the <italic>bla</italic><sub>DHA-1</sub> gene bears a substantial fitness cost (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In addition, we found that the OmpK36 inactivating mutation reduced fitness in ceftazidime, confirming that selection on ceftazidime can select for the <italic>bla</italic><sub>DHA-1</sub> gene, but not for the <italic>ompK36</italic> mutation, which is required for imipenem resistance.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Competitive fitness assay of FK688 strain variants in the presence of ceftazidime.</title><p>(<bold>A</bold>) The fitness of FK688 mutants measured in Lysogeny Broth (LB) media supplemented with ceftazidime across a concentration range from 0.125 to 2 µg/mL. Only strains with an intact pNAR1 plasmid, including the <italic>bla</italic><sub>DHA-1</sub> gene, are able to survive high concentrations of ceftazidime. The legend has the genotypes for the <italic>Klebsiella</italic> strains. Error bars represent mean with ± SD (n=4). (<bold>B</bold>) Schematic of the imipenem resistance landscape. Each genotype is depicted as being resistant (red) or susceptible (blue) to imipenem. The x and y planes depict the antimicrobial resistance (AMR) genotypes, and the z plane represents growth measured at each concentration of imipenem. Circles represent the genotype of each strain, and lines show strain connected by a single mutation. The evolution of imipenem resistance requires two genes - the <italic>bla</italic><sub>DHA-1</sub> gene, and a loss of function mutation in <italic>ompK36</italic>: these two alleles are both found in FK688, indicated at “D”. Since both single-step mutants “B” and “C” are imipenem susceptible and do not have a fitness advantage in growth media without drugs (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), we propose that the population had recently been exposed to conditions that selected for the pNAR1 plasmid. Then after exposure of the population to imipenem, the Δ<italic>ompK36</italic> mutant was strongly selected. This suggests that the most likely evolutionary path to imipenem resistance was A → B → D.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Relative fitness values for each data point in <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>Data used to construct fitness landscape in <xref ref-type="fig" rid="fig6">Figure 6B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-83107-fig6-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83107-fig6-v1.tif"/></fig><p>These results support the hypothesis that imipenem resistance evolved in FK688 via multiple evolutionary steps. First, the population experienced an antibiotic-containing environment that selected for the <italic>bla</italic><sub>DHA-1</sub> gene. This could have been any antibiotic that selected for the pNAR1 plasmid, such as ceftazidime or another β-lactam antibiotic. After a short period of selection on this first treatment, most of the population would carry the <italic>bla</italic><sub>DHA-1</sub> gene, increasing the chance that an <italic>ompK36</italic> inactivating mutation would occur in a cell that also carried the <italic>bla</italic><sub>DHA-1</sub> gene. We tested the evolutionary potential for each genotype to evolve imipenem resistance by setting up cultures of the FK688 strains with either one, or none, of the two drug resistance alleles and plating 10<sup>9</sup> cells of each genotype on a range of concentrations of imipenem (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>). We evaluated the evolutionary path to antibiotic resistance by considering the starting point of evolution as the genotype that does not have the <italic>bla</italic><sub>DHA-1</sub> gene or the loss of function mutation in <italic>ompK36</italic>, indicated at “A”. This genotype is the most logical starting point because it has the highest fitness in growth conditions without antibiotic (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). We found that strains that carried only the Δ<italic>ompK36</italic> allele, or neither allele, were unable to evolve imipenem resistance (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; “A” and “C”). However, a <italic>K. quasipneumoniae</italic> strain with the pNAR1 plasmid (carrying the <italic>bla</italic><sub>DHA-1</sub> gene) would be readily able to evolve resistance (<xref ref-type="fig" rid="fig6">Figure 6B</xref>; “B”). Thus, in a scenario representing previous treatment of a patient with ceftazidime, given the low fitness benefit conferred by the loss of function mutation in <italic>ompK36</italic> in growth media supplemented with imipenem, the path A → B → D is most likely.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study presented the first physical genetic map of a <italic>K. quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> genome. In addition to species-specific AMR loci on the bacterial chromosome, this multidrug-resistant strain carries many characterised AMR traits on a megaplasmid that was named pNAR1. We have further used whole genome sequencing of <italic>K. quasipneumoniae</italic> populations to characterise the genetic and evolutionary mechanism with which they acquire carbapenem resistance. A major finding of the study is the ease with which carbapenem sensitivity was restored in the absence of drug selection. This bodes well for new strategies that are being devised to reverse the evolution of AMR phenotypes in <italic>Klebsiella</italic> spp. populations, be they in built environments, in gut microbiomes or in infection sites. A further major finding is the means by which an ill-chosen drug treatment, for example with ceftazidime, can prime a population of <italic>K. quasipneumoniae</italic> to rapidly evolve a CRE phenotype.</p><p>Genomics-based surveillance has shown that KPC-2 carbapenemases are widespread in <italic>Klebsiella</italic> spp. including <italic>K. quasipneumoniae</italic> (<xref ref-type="bibr" rid="bib54">Mathers et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Octavia et al., 2019</xref>). β-lactamases encoded by chromosomal genes are common amongst these species of <italic>Klebsiella: bla</italic><sub>SHV</sub> is found in <italic>K. pneumoniae</italic>, <italic>bla</italic><sub>OKP-A</sub> in <italic>K. quasipneumoniae</italic> subsp. <italic>quasipneumoniae</italic> and <italic>bla</italic><sub>OKP-B</sub> in <italic>K. quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> (<xref ref-type="bibr" rid="bib71">Rodrigues et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Long et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Fevre et al., 2005</xref>). Consistent with this, FK688 carries a chromosomally located <italic>bla</italic><sub>OKP-B.</sub> In addition, FK688 also carries the β-lactamase <italic>bla</italic><sub>DHA-1</sub> on the megaplasmid pNAR1.</p><sec id="s3-1"><title>Epistatic impacts of porins, pumps, and enzymes on carbapenem-resistance</title><p>There have been no reports on drug efflux pumps in <italic>K. quasipneumoniae</italic>, but in some strains of <italic>K. pneumoniae</italic>, drug-resistance phenotypes have been suggested to include epistatic contributions from genes encoding efflux pumps (<xref ref-type="bibr" rid="bib58">Nicolas-Chanoine et al., 2018</xref>). FK688 encodes numerous ABC-type efflux systems with annotations for these efflux pumps suggestive of metal ion ligands (copper, silver, and mercury), but the ligand specificity of efflux pumps can be broader or different to that denoted by annotation (<xref ref-type="bibr" rid="bib52">Mata et al., 2000</xref>; <xref ref-type="bibr" rid="bib27">Flach et al., 2017</xref>). In FK688, the efflux pumps did not contribute to carbapenem resistance. Are there any further epistatic effects relevant to imipenem sensitivity? A potential one would be that other porins had been upregulated, and the A2(t) translucent strain was observed to have increased expression of outer membrane proteins OmpA and PhoE (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). However, (i) OmpA does not form a sizeable channel in the outer membrane (<xref ref-type="bibr" rid="bib62">Ortiz-Suarez et al., 2016</xref>), and (ii) while the porin PhoE does form a channel (<xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref>), it is not conducive to permitting imipenem entry into <italic>Klebsiella</italic> (<xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref>). A single SNP that was fixed in the A2 population was in the <italic>cadBA</italic> operon that generates cadaverine (<xref ref-type="supplementary-material" rid="fig5sdata3">Figure 5—source data 3</xref>). CadC is a positive activator of the <italic>cadBA</italic> operon (<xref ref-type="bibr" rid="bib19">DelaVega and Delcour, 1995</xref>), and this activation of <italic>cadBA</italic> is known to close porins in general and block β-lactam influx (<xref ref-type="bibr" rid="bib20">Dela Vega and Delcour, 1996</xref>; <xref ref-type="bibr" rid="bib41">Iyer and Delcour, 1997</xref>; <xref ref-type="bibr" rid="bib73">Samartzidou et al., 2003</xref>), with point mutations in the CadC protein sufficient to inhibit the <italic>cadBA</italic> operon (<xref ref-type="bibr" rid="bib75">Schlundt et al., 2017</xref>).</p><p>Instead, we found that the CRE phenotype in FK688 depends on epistasis between <italic>bla</italic><sub>DHA-1</sub> and <italic>ompK36</italic>. Both the carriage of <italic>bla</italic><sub>DHA-1</sub> and the defect in <italic>ompK36</italic> have measurable fitness cost to the strain. After multiple rounds of plating in the absence of drug-selection, we observed the loss of a segment <italic>(tnpA-sul1</italic>) of pNAR1 that carries <italic>bla</italic><sub>DHA-1</sub>, that is, selection against the β-lactamase. This same outcome was also observed in a controlled evolution experiment over 200 generations. These observations are explained by the measured fitness cost in pNAR1<italic>Δbla</italic><sub>DHA-1</sub> which was less than the fitness cost imparted by the full plasmid. Thus, in the absence of β-lactam, the CRE phenotype is reversed to carbapenem-sensitivity. It is not clear from current literature how widespread the non-carbapenemase CRE phenotype is, but several points are worthy of note: (i) the presence of plasmids encoding DHA-1 is geographically wide-spread (<xref ref-type="bibr" rid="bib37">Hennequin et al., 2012</xref>), (ii) the presence of <italic>ompK35</italic> and/or <italic>ompK36</italic> mutations is prevalent in the various species of <italic>Klebsiella</italic> (<xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref>), and (iii) a recent case study showed a single hospital had collected 87 isolates of CRE <italic>Klebsiella</italic> with 55% of them being a non-carbapenemase CRE phenotype (<xref ref-type="bibr" rid="bib82">Tamma et al., 2017a</xref>).</p></sec><sec id="s3-2"><title>Diagnosis and treatment of non-carbapenemase CRE</title><p>To obtain the best outcome from the limited treatment options effective against CRE, a personalised approach to antibiotic dosing has been urged (<xref ref-type="bibr" rid="bib22">Doi, 2019</xref>; <xref ref-type="bibr" rid="bib21">Doi and Paterson, 2015</xref>; <xref ref-type="bibr" rid="bib69">Reyes and Nicolau, 2020</xref>). This in turn requires rapid and accurate diagnosis. All of the currently available tests for CRE aim to identify specific carbapenemases: the Carba NP test detects OXA-48 type carbapenemases, the modified Hodge test identifies metallo-β-lactamases (<xref ref-type="bibr" rid="bib46">Kuchibiro et al., 2018</xref>), and the newer more sophisticated gene-specific tests also have limitations (<xref ref-type="bibr" rid="bib83">Tamma et al., 2017b</xref>; <xref ref-type="bibr" rid="bib65">Powell et al., 2017</xref>; <xref ref-type="bibr" rid="bib68">Revez et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Hong et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Meunier et al., 2018</xref>). The finding that in some environments perhaps half of all CRE cases could be caused by strains that do not encode a carbapenemase (<xref ref-type="bibr" rid="bib82">Tamma et al., 2017a</xref>), and our finding that DHA-1 expression can - through epistasis with porin mutations - deliver a CRE phenotype adds a further degree of difficulty to diagnosis of CRE.</p><p>While treatment options for CRE are limited (<xref ref-type="bibr" rid="bib69">Reyes and Nicolau, 2020</xref>; <xref ref-type="bibr" rid="bib77">Sheu et al., 2019</xref>), this study adds benefit in two important aspects. First, combination therapy using an ESBL inhibitor such as avibactam or tazobactam could be a good option for this type of CRE (<xref ref-type="bibr" rid="bib91">Yahav et al., 2020</xref>). For example, the use of ceftolozane-tazobactam combination therapy is suggested as an alternative to carbapenems in treatment of some CRE infections (<xref ref-type="bibr" rid="bib29">Giacobbe et al., 2018</xref>), and a cohort study of 391 patients with ceftriaxone-resistant infections showed piperacillin-tazobactam combination therapy compared favourably with carbapenem treatment (<xref ref-type="bibr" rid="bib36">Harris et al., 2018</xref>). In strains like FK688, where it is a β-lactamase such as DHA-1 that contributes to carbapenem resistance, specific inhibition of that β-lactamase with avibactam or tazobactam would increase the level of carbapenem or cephalosporin in the bacterial periplasm and thereby increase the effectiveness of drug treatment. Second, our study cautions that moves towards phage therapy being used to treat CRE should avoid the use of phages that use OmpK35 or OmpK36 as their receptor (<xref ref-type="bibr" rid="bib72">Rosas and Lithgow, 2022</xref>). These phages would place selective pressure on the <italic>Klebsiella</italic> strain to become porin-defective since mutations to inactivate the receptor is a prime cause of phage-resistance (<xref ref-type="bibr" rid="bib32">Gordillo Altamirano et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Gordillo Altamirano and Barr, 2021</xref>). Phages that use OmpK35 or OmpK36 as their receptor would thereby select for porin-defects and thus inadvertently select for carbapenem-resistance; phages used therapeutically should therefore target alternate receptors (<xref ref-type="bibr" rid="bib72">Rosas and Lithgow, 2022</xref>).</p><p>Finally, this study shows how the evolutionary history of a pathogenic strain can predispose for an AMR phenotype to evolve via specific genetic routes. The likelihood that antibiotic resistance will evolve depends on the strength of selection and the availability of genetic variants that confer resistance to the antibiotic. If the genes or genetic variants that confer resistance to the antibiotic confer a decrease in fitness in environments without antibiotic, then these variants will be exceedingly rare (or absent) from the population. If antibiotic resistance genes are not supplied via horizontal gene transfer, then antibiotic resistance must evolve by the de novo mutation of a gene already present in the genome. Since the spontaneous acquisition of multiple genetic variants (for example,Δ<italic>ompK36</italic> and <italic>bla</italic><sub>DHA-1</sub>) is much less likely than the acquisition of a single new gene (KPC-2 carbapenemase), the evolution of non-carbapenem resistance via two loci seemed unlikely. However, if a strain already carries the <italic>bla</italic><sub>DHA-1</sub> gene then the spontaneous evolution of a loss-of-function mutation in an extant chromosomal gene - <italic>ompK36</italic> - is more likely than the spontaneous acquisition of a carbapenemase gene. Exposure to ceftazidime, or any antibiotic that selects for the <italic>bla</italic><sub>DHA-1</sub> gene, would therefore potentiate the evolution of carbapenem resistance by a single loss-of-function mutation in major porins. These results show how an individual’s treatment history might shape the evolution of AMR and should be taken into consideration in order to explain the evolution of non-carbapenemase CRE.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Chemicals and reagents</title><p>Ampicillin and tetracycline were purchased from Astral Scientific. All other antibiotics were purchased from Sigma-Aldrich in highest possible grade. A stock solution of Anhydrotetracycline (Cayman Chemical Company) in 50% ethanol was prepared to induce β-lactamase production when required.</p></sec><sec id="s4-2"><title>Bacterial strains, oligonucleotides, and cultures conditions</title><p>Plasmids, bacterial strains, and oligonucleotides used in this study are described in <xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="table" rid="table5">Table 5</xref>, and <xref ref-type="table" rid="table6">Table 6</xref>, respectively. Bacterial cultures were routinely grown in Lysogeny Broth (LB) or cation-adjusted Mueller-Hinton Broth (CAMHB) media at 37°C with shaking at 200 rpm, unless otherwise stated. When required, antibiotics used for the selection of antibiotic resistance markers were supplemented in growth media at the following concentrations: ampicillin 100 μg/mL; kanamycin 30 μg/mL; chloramphenicol 34 μg/mL; ceftazidime: 0.125 μg/mL, 0.25 μg/mL, 0.5 μg/mL, 1 μg/mL, or 2 μg/mL; imipenem: 0.03 μg/mL, 0.06 μg/mL, 0.125 μg/mL, 0.25 μg/mL, or 0.5 μg/mL.</p><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>List of plasmids used in this study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Plasmid</th><th align="left" valign="bottom">Relevant characteristics<xref ref-type="table-fn" rid="table4fn1">*</xref></th><th align="left" valign="bottom">Source/reference</th></tr></thead><tbody><tr><td align="left" valign="bottom">pKD4</td><td align="left" valign="bottom">Contains kanamycin resistance cassette (<italic>kan</italic>) flanked by FRT sites (FRT-<italic>kan</italic>-FRT); <italic>oriR6K</italic>, Amp<sup>R</sup>, Km<sup>R</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib18">Datsenko and Wanner, 2000</xref></td></tr><tr><td align="left" valign="bottom">pJET1.2/blunt</td><td align="left" valign="bottom">Blunt-end cloning vector for insertion of DNA fragments with single deoxyadenosine overhangs; Amp<sup>R</sup></td><td align="left" valign="bottom">Thermo Scientific</td></tr><tr><td align="left" valign="bottom">pDonor(OmpK36)</td><td align="left" valign="bottom">pJET1.2/blunt carrying FRT-<italic>kan</italic>-FRT and <italic>K. quasipneumoniae</italic> FK688 <italic>ompK36</italic> regions (donor plasmid for lambda Red recombination-mediated repair of <italic>ompK36</italic> gene in FK688); Amp<sup>R</sup>, Km<sup>R</sup></td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pACBSR</td><td align="left" valign="bottom">Arabinose-inducible promoter; I-<italic>Sce</italic>I endonuclease; lambda Red recombination genes, Cm<sup>R</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Herring et al., 2003</xref></td></tr><tr><td align="left" valign="bottom">pFLP-BSR</td><td align="left" valign="bottom">pACBSR carrying fragment length polymorphism (FLP) recombinase to excise the kanamycin cassette, temp-sensitive replication; Cm<sup>R</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref></td></tr><tr><td align="left" valign="bottom">pJP-CmR</td><td align="left" valign="bottom">Derivative of pJP168 for anhydrotetracycline inducible protein expression. Cm<sup>R</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib70">Rocker et al., 2020</xref></td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>bla</italic><sub>DHA-1</sub> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>OKP-B-21</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>bla</italic><sub>OKP-B-21</sub> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>SHK</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>CKCOFDID_01495</italic> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>OPHC</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>CKCOFDID_02113</italic> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>DAE</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>pbpG</italic> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>TRN</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>CKCOFDID_04153</italic> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>ABH</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>dhmA</italic> from FK688</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">pJP-<italic>bla</italic><sub>DAC</sub></td><td align="left" valign="bottom">pJP-Cm containing <italic>dacB</italic> from FK688</td><td align="left" valign="bottom">This study</td></tr></tbody></table><table-wrap-foot><fn id="table4fn1"><label>*</label><p>Amp, ampicillin; Km, kanamycin; Cm, chloramphenicol.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>List of strains used in this study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Strain</th><th align="left" valign="bottom">Relevant characteristics<xref ref-type="table-fn" rid="table5fn1">*</xref></th><th align="left" valign="bottom">Source or reference</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold><italic>K. quasipneumoniae</italic></bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"><bold>FK688</bold> Δ<italic>ompK36</italic> pNAR1</td><td align="left" valign="bottom">Wildtype, clinical isolate from a bloodstream infection case from the First Affiliated Hospital of Wenzhou Medical University, China. Expresses β-lactamase <italic>bla</italic><sub>OKP-B-21</sub>. Deficient in <italic>ompK35</italic> and <italic>ompK36</italic> porin expression. Harbours a 258 kb plasmid pNAR1 (Amp<sup>R</sup>, Tet<sup>R</sup>, Rif<sup>R</sup>, Trp<sup>R</sup>, Stp<sup>R</sup>, Ery<sup>R</sup>, Sdz<sup>R</sup>, Cip<sup>R</sup>).</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib5">Bi et al., 2017</xref></td></tr><tr><td align="left" valign="bottom">Δ<italic>ompK36</italic> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">FK688 with a 17 kb deletion from <italic>tnpA-sul1</italic> in pNAR1.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">Δ<italic>ompK36</italic> pNAR1<sup>–</sup></td><td align="left" valign="bottom">FK688 cured of pNAR1.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom"><italic>ompK36</italic><sup>+</sup> pNAR1</td><td align="left" valign="bottom">FK688 with a genetically repaired and functional <italic>ompK36</italic> gene. Carries pNAR1.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom"><italic>ompK36</italic><sup>+</sup> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">FK688 with a genetically repaired and functional <italic>ompK36</italic> gene. It has a 17 kb deletion from <italic>tnpA-sul1</italic> in pNAR1.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">FK688-GFP<bold><sup>+</sup></bold></td><td align="left" valign="bottom">FK688 with a constitutively expressed green fluorescent protein (GPF). GFP gene inserted downstream of the <italic>glmS</italic> gene via pGRG-eGFP.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">A2(o)<break/>Δ<italic>ompK36</italic> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">Evolved strain from Kq1. It has a 17 kb deletion from <italic>tnpA-sul1</italic> in pNAR1. Forms opaque colonies.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">A2(t)<break/>Δ<italic>ompK36</italic> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">Evolved strain from Kq1. It has a 17 kb deletion from <italic>tnpA-sul1</italic> in pNAR1. Forms translucent colonies.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">B3(o) <italic>ompK36</italic><sup>+</sup> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">Evolved strain from Kq4. It has a 17 kb deletion from <italic>tnpA-sul1</italic> in pNAR1. Forms opaque colonies.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom">B3(t) <italic>ompK36</italic><sup>+</sup> pNAR1Δ<italic>bla</italic><sub>DHA-1</sub></td><td align="left" valign="bottom">Evolved strain from Kq4. It has a 17 kb deletion from <italic>tnpA-sul1</italic> in pNAR1. Forms translucent colonies.</td><td align="left" valign="bottom">This study</td></tr><tr><td align="left" valign="bottom"><bold><italic>K. pneumoniae</italic></bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">B5055</td><td align="left" valign="bottom">Hypermucoviscous phenotype. Wildtype, clinical isolate, serotype K2;O1</td><td align="left" valign="bottom">Statens Serum Institut, Denmark</td></tr><tr><td align="left" valign="bottom">B5055 nm</td><td align="left" valign="bottom">B5055 deletion mutant ∆wza-wzc::km (non-mucoid); Km<sup>R</sup></td><td align="left" valign="bottom">Prof. Richard Strugnell University of Melbourne</td></tr><tr><td align="left" valign="bottom"><bold><italic>E. coli</italic></bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">DH5α</td><td align="left" valign="bottom">F<sup>–</sup> endA1 <italic>hsd</italic>R17(r<sub>K</sub><sup>–</sup>, m<sub>K</sub><sup>+</sup>) <italic>sup</italic>E44 λ– <italic>thi</italic>-1 <italic>rec</italic>A1 <italic>gyr</italic>A96 <italic>rel</italic>A1 <italic>deoR</italic> Δ(<italic>lac</italic>ZYA-<italic>arg</italic>F) U169 Φ80<italic>dlac</italic>Z∆M15; Nal<sup>R</sup><break/><italic>E. coli</italic> DH5α was used for cloning purposes</td><td align="left" valign="bottom">Invitrogen</td></tr><tr><td align="left" valign="bottom">ATCC 25922</td><td align="left" valign="bottom">CLSI control strain for antimicrobial susceptibility testing</td><td align="left" valign="bottom">ATCC</td></tr><tr><td align="left" valign="bottom">BW25113 (WT)</td><td align="left" valign="bottom"><italic>rrn</italic>B3 Δ<italic>lac</italic>Z4787(::rrnB-3) <italic>hsd</italic>R514 Δ(<italic>araD-araB</italic>)567 Δ(<italic>rhaD-rhaB</italic>)568, <italic>rph</italic>-1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib3">Baba et al., 2006</xref></td></tr></tbody></table><table-wrap-foot><fn id="table5fn1"><label>*</label><p>Amp, ampicillin; Tet, tetracycline; Rif, rifamycin; Trp, trimethoprim; Stp, streptomycin; Ery, erythromycin; Sdz, sulfadiazine; Cip, ciprofloxacin; Nal, nalidixic acid.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table6" position="float"><label>Table 6.</label><caption><title>List of oligonucleotide primers used in this study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Primer</th><th align="left" valign="bottom">Sequence (5–3’)<xref ref-type="table-fn" rid="table6fn1">*</xref></th><th align="left" valign="bottom">Description</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="2"><bold>Construction of FK688 OmpK36<sup>+</sup> strains</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">K36_insert-R</td><td align="left" valign="bottom">gcgcgacctactacttcaacaaaaacatgtccacctatgttgactacaaaatcaacctgctg</td><td align="left" valign="bottom" rowspan="6">Construction of pDonor(OmpK36) plasmid</td></tr><tr><td align="left" valign="bottom">K36_insert-F</td><td align="left" valign="bottom">gttgaagtagtaggtcgcgcccacgtcaacatatttcaggatgtcctggtcgcc</td></tr><tr><td align="left" valign="bottom">K36_Km-F</td><td align="left" valign="bottom">ctaaggaggatattcatatggtcgcaagctgcataacaaa</td></tr><tr><td align="left" valign="bottom">K36_Km-R</td><td align="left" valign="bottom">gaagcagctccagcctacacattagaactggtaaaccaggcccag</td></tr><tr><td align="left" valign="bottom">K36_ISceI-R</td><td align="left" valign="bottom">tagggataacagggtaatgcccgacggtgatatccatc</td></tr><tr><td align="left" valign="bottom">K36_ISceI-F</td><td align="left" valign="bottom">tagggataacagggtaatgcttcggtacctctgtaacttatga</td></tr><tr><td align="left" valign="bottom">pKD4-F</td><td align="left" valign="bottom">tgtgtaggctggagctgcttc</td><td align="left" valign="bottom" rowspan="2">Kanamycin cassette from pKD4</td></tr><tr><td align="left" valign="bottom">pKD4-R</td><td align="left" valign="bottom">catatgaatatcctccttag</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Cloning of putative β-lactamases genes for anhydrotetracycline-inducible expression</bold></td></tr><tr><td align="left" valign="bottom">blaDHA-1_For_NR</td><td align="left" valign="bottom">gtccCCATGGtgaaaaaatcgttatctgcaac</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaDHA-1_Rev_NR</td><td align="left" valign="bottom">cgtcAAGCTTattccagtgcactcaaa</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaOKP_F_NR</td><td align="left" valign="bottom">tagcGAATTCatgcgttatgttcgcctgtgcc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaOKP_R_NR</td><td align="left" valign="bottom">gcatAAGCTTctagcgctgccagtg</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaSHK1_F_NR</td><td align="left" valign="bottom">gttcCCATGGtgataagaaaaccactggcc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaSHK1_R_NR</td><td align="left" valign="bottom">atgcAAGCTTaacgcagctcgcg</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaOPHC2_F_NR</td><td align="left" valign="bottom">ctagGAATTCatgacaccagctcccttttataccctgac</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaOPHC2_R_NR</td><td align="left" valign="bottom">acggAAGCTTtcgctgtgatcggtgtt</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaDAE1_F_NR</td><td align="left" valign="bottom">tgcaGAATTCatgatgccgaaatttcgagtctctttgc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaDAE1_R_NR</td><td align="left" valign="bottom">gatcAAGCTTttaatcgttctgcgcg</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaABH1_F_NR</td><td align="left" valign="bottom">acgtCCATGGTGaacagattatccctgatcc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaABH1_R_NR</td><td align="left" valign="bottom">gatcAAGCTTacaaccgatcggcg</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaDAC1_F_NR</td><td align="left" valign="bottom">aaggCCATGGtgcgatttcccagatttatc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaDAC1_R_NR</td><td align="left" valign="bottom">aagcAAGCTTtagttgttctggtacaaatcc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaTRN1_F_NR</td><td align="left" valign="bottom">cgtaCCATGGtgactgaacgggtttattacac</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">blaTRN1_R_NR</td><td align="left" valign="bottom">aatcAAGCTTacgtcagggaatagctgatc</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">pJPMCS_For</td><td align="left" valign="bottom">cctaatttttgttgacactctatcattg</td><td align="left" valign="bottom" rowspan="2">pJP-CmR-gene insert sequencing primers</td></tr><tr><td align="left" valign="bottom">pJPMCS_Rev</td><td align="left" valign="bottom">gccaggcaaattctgttttatcagaccg</td></tr></tbody></table><table-wrap-foot><fn id="table6fn1"><label>*</label><p>Restriction endonuclease recognition sites are capitalised.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4-3"><title>Genome sequencing and evaluation</title><p>gDNA of the <italic>Klebsiella</italic> isolates was prepared from solid media scrapings of pure culture using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich) and the Gram-negative bacteria protocol. High molecular weight DNA was then isolated using a 0.6× ratio of sample (200 µLl) to AMPure XP-beads (120 µL; A63882, Beckman Coulter). gDNA was sequenced in parallel on the Oxford Nanopore GridION and Illumina Nextseq 500. High molecular weight DNA was prepared as a Nanopore sequencing library, according to the manufacturer’s protocols using a ligation sequencing kit (SQK-LSK109, Oxford Nanopore), with minor modifications. All mixing steps for the DNA sample were done by gently flicking the microfuge tube instead of pipetting, and the optional shearing step was omitted.</p><p>DNA repair treatment was carried out using NEBNext FFPE DNA Repair Mix (M6630, New England Biolabs). End repair and A-tailing were performed with NEBNext Ultra II End Repair/dA-tailing Module (E7546, New England Biolabs), and the sample was incubated at 20°C for 5 min and then 65°C for 5 min. End-repaired product was purified with 1×Agencourt AMPure XP beads.</p><p>Adapters provided in the respective library kits were ligated to the DNA with Quick T4 DNA Ligase (M2200L, New England Biolabs), and samples were incubated at room temperature for 10 min. Purification and loading of adapted libraries on an appropriate flow cell (R9.4.1, FLO-MIN106D, Oxford Nanopore) were completed as stated in the manufacturer’s protocol and sequenced using the appropriate MinKNOW workflow. The library was base-called using Guppy (ont-guppy-for-gridion, 3.0.6). Reads with a length less than 1000 bp were discarded. The sample had an estimated Nanopore coverage of 884-fold, with an average read length of 7445 bp and a range of 1000–191,716 bp.</p><p>Illumina sequences were prepared on a NextSeq 500 platform, with 150 bp paired-end chemistry. Reads were trimmed to remove adaptor sequences and low-quality bases with <ext-link ext-link-type="uri" xlink:href="https://github.com/timflutre/trimmomatic">Trimmomatic</ext-link> (<xref ref-type="bibr" rid="bib7">Bolger et al., 2015</xref>), with <ext-link ext-link-type="uri" xlink:href="https://github.com/DerrickWood/kraken">Kraken</ext-link> used to investigate contamination ( <xref ref-type="bibr" rid="bib87">Wood and Lu, 2015</xref>, v0.10.5-beta).</p><p>Assembly involved long-read-only assembly of long reads, followed by short-read correction. In brief, Nanopore reads were downsampled using Filtlong (<xref ref-type="bibr" rid="bib85">Wick and Menzel, 2018</xref>, v0.2.0) to retain the highest quality reads (10% of all, equivalent to an estimated 88-fold coverage). These reads were assembled using <ext-link ext-link-type="uri" xlink:href="https://github.com/marbl/canu">Canu</ext-link> (<xref ref-type="bibr" rid="bib45">Koren S et al., 2018</xref>, v1.8), with an expected genome size of 5,000,000 bp. The assembled contigs output by Canu were circularised where appropriate and validated through a read mapping approach in Geneious Prime (2019.2.1) before short-read correction. The corrected assembly was oriented to <italic>dnaA</italic> and annotated using <ext-link ext-link-type="uri" xlink:href="https://github.com/tseemann/prokka">Prokka</ext-link> (<xref ref-type="bibr" rid="bib76">Seemann, 2020</xref>). The sample had varied coverage across assembled molecules, ranging in Illumina coverage between 156-fold for the chromosome and 188-fold for the plasmid.</p></sec><sec id="s4-4"><title>Plasmid annotation</title><p>Prokka v1.14.0 was employed to predict pNAR1 genes. The translated gene sequences were used to search against NCBI nr and CARD resistance databases (Comprehensive Antibiotic Resistance Database) with the blastp algorithm and <ext-link ext-link-type="uri" xlink:href="https://github.com/arpcard/rgi">Resistance Gene Identiﬁer</ext-link> software (<xref ref-type="bibr" rid="bib2">Alcock et al., 2020</xref>), respectively (e value≤10<sup>–5</sup>). The predicted genes received an annotation file containing credible resistance genes (cut-off as “Perfect” or “Strict”) and putative resistance genes (cut-off as “Loose”).</p></sec><sec id="s4-5"><title>Membrane protein analysis</title><sec id="s4-5-1"><title>Membrane purification and isolation</title><p>Overnight cultures of strains were diluted 1:100 in 200 mL CAMHB and grown until OD<sub>600</sub> = ~0.5. Cells were harvested by centrifugation (10,000 × <italic>g</italic>, 10 min, 4°C) and resuspended in 10 mM Tris-HCl, pH 7.5. The centrifugation was repeated, and cells resuspended in Tris-Sucrose buffer (10 mM Tris-HCl, pH 7.5, 0.75 M sucrose). Peptidoglycan was degraded at a final concentration of 50 µg/mL lysozyme, and host serine proteases were inhibited at a final concentration of 2 mM phenylmethylsulfonyl fluoride. The outer membrane was destabilised for lysis in two volumes of 1.65 mM EDTA, pH 7.5. Cells were incubated on ice for 10 min and then lysed using an AVESTIN Emulsiflex-C3 (4 passes at ~15,000 psi). Cell lysates were centrifuged (15,000 × <italic>g</italic>, 20 min, 4°C) to remove cell debris. The supernatant was collected, and total membranes were pelleted by ultracentrifugation (132,000 × <italic>g</italic>, 45 min, 4°C) using a 70.1 Ti rotor. Membrane pellets were resuspended and pooled from duplicate samples in ~8 mL TES buffer (2.2 mM Tris-HCl, pH 7.5, 1.1 mM EDTA, and 0.25 M sucrose) and ultracentrifuged as before. Membrane pellets were resuspended in 200 µL of 25% sucrose in 5 mM EDTA, pH 7.5, and stored at −80°C.</p></sec><sec id="s4-5-2"><title>Protein expression and analysis</title><p>Total (outer and inner) membranes from <italic>K. quasipneumoniae</italic> were purified following the method of <xref ref-type="bibr" rid="bib23">Dunstan et al., 2017</xref> with minor modifications. Membrane proteins were quantified with a NanoDrop 1000 Spectrophotometer (Thermo Scientific) and standardised to equivalent concentrations. Samples (~2 µg) were loaded onto a sSDS-PAGE containing 11% (wt/vol) 37.5:1 acrylamide-bisacrylamide, 0.375 M Tris (pH 8.8), 0.1% (wt/vol) SDS, and 0.5 mM EDTA in the separating gel and 4% (wt/vol) 37.5:1 acrylamaide-bisacrylamide, 0.25 M Tris (pH 6.8), 0.1% (wt/vol) SDS, and 0.5 mM EDTA in the stacking gel.</p><p>Proteins (~2 µg) were transferred to a 0.2 µm nitrocellulose membrane (Bio-Rad) using a Trans-Blot Turbo Transfer System (Bio-Rad; 0.6 A, 25 V, 15 min), which was blocked overnight in TBST (tris-buffered saline; 0.1% Tween 20) containing 5% skim milk.</p><p>OmpK36 was detected by western blot using polyclonal antibodies raised in rabbits against the <italic>E. coli</italic> homolog OmpC, which is cross-reactive to OmpK35 and OmpK36 in <italic>Klebsiella</italic>. For use as a loading control, the outer-membrane protein BamD was detected using a ⍺-BamD antibody raised in rabbits against the <italic>E. coli</italic> BamD homolog. Goat Anti-Rabbit IgG antibody, HRP-conjugate (Sigma-Aldrich) was used as the secondary antibody. All antibodies were used at a 1:20,000 dilution in TBST containing 2% skim milk. Proteins were detected by chemiluminescence.</p></sec></sec><sec id="s4-6"><title>MIC determination</title><p>Antimicrobial susceptibility testing was performed by broth microdilution method using CAMHB according to the guidelines the Clinical and Laboratory Standards Institute (CLSI) M07-10th Ed. Document <xref ref-type="bibr" rid="bib15">CLSI, 2015</xref>. The resistance of antimicrobial agents was interpreted according to the criteria of <xref ref-type="bibr" rid="bib16">CLSI, 2022</xref>. The assays were performed in biological triplicate with at least two technical replicates. <italic>E. coli</italic> ATCC 25922 was used as a quality-control strain.</p></sec><sec id="s4-7"><title>Mutant construction</title><p>A <italic>K. quasipneumoniae</italic> FK688 strain containing a repaired <italic>ompK36</italic> gene (<italic>ompK36</italic><sup>+</sup>) was constructed using the “gene gorging” technique (<xref ref-type="bibr" rid="bib38">Herring et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Cherepanov and Wackernagel, 1995</xref>; <xref ref-type="bibr" rid="bib47">Lee et al., 2009</xref>; <xref ref-type="bibr" rid="bib18">Datsenko and Wanner, 2000</xref>). A donor plasmid was made that contained the repaired <italic>ompK36</italic> gene upstream of a kanamycin-resistant cassette and ~500 bp of FK688 genomic region downstream of the <italic>ompK36</italic> gene and flaked by I-<italic>Sce</italic>I- endonuclease recognition sites. The PCR products were gel purified, cloned into pJET1.2/blunt, and confirmed by sequencing. The primers used are listed in <xref ref-type="table" rid="table6">Table 6</xref>. The donor plasmid and pACBSR carrying L-arabinose-inducible I-<italic>Sce</italic>I endonuclease and λ-Red recombinase genes were transformed into FK688 by electroporation. Co-transformants were inoculated into LB containing chloramphenicol and 0.2% (<italic>w/v</italic>) L-arabinose and incubated overnight at 30°C with shaking. Engineered strains were isolated on LB-agar containing kanamycin and cured of the donor and pACBSR plasmids (by their sensitivity to chloramphenicol), and mutants were confirmed by PCR. The self-curing plasmid pFLP-BSR was then used to excise the kanamycin cassette (<xref ref-type="bibr" rid="bib14">Cherepanov and Wackernagel, 1995</xref>).</p></sec><sec id="s4-8"><title>Validation testing of candidate β-lactamases</title><p>The coding sequences of β-lactamase and DeepBL candidate genes were amplified from FK688 gDNA using Fusion High-Fidelity DNA polymerase (New England BioLabs) with the oligonucleotide primers listed in <xref ref-type="table" rid="table6">Table 6</xref>. The PCR products and the anhydrotetracycline (ATc)-inducible expression vector pJP-CmR were digested with restriction enzymes using either <italic>Nco</italic>I and <italic>Hin</italic>dIII, or <italic>Eco</italic>RI and <italic>Hin</italic>dIII (New England BioLabs) and ligated to create the plasmids listed in <xref ref-type="table" rid="table5">Table 5</xref>. Plasmids were verified by sequencing, transformed into <italic>E. coli</italic> BW25113 or <italic>K. quasipneumoniae</italic> FK688, and selected with chloramphenicol. Target gene expression was induced with 35 ng/mL ATc. The parental plasmid pJP-CmR was used as the control in all experiments.</p></sec><sec id="s4-9"><title>Plasmid maintenance assessment</title><p>A mutation accumulation experiment was performed to evaluate pNAR1 stability in the FK688 Δ<italic>ompK36</italic> pNAR1 strain. The strain was cultured on LB agar (no antibiotics) from a glycerol stock, corresponding to passage #1 (P1). From this plate, 10 colonies were replica cultured on LB agar containing 10 µg/mL ceftazidime (LB-CAZ) and LB agar without antibiotics (LB-only). Five colonies from P1 were individually subcultured on five LB agar plates without antibiotics (P2). One colony from each P2 plate was similarly passaged to P20, with replica plating of 10 colonies on LB-CAZ and LB-only after each passage. Therefore, 50 colonies were screened after each passage. Colonies that grew on LB-only but not on LB-CAZ (CAZS) were assessed for pNAR1 maintenance by PCR.</p></sec><sec id="s4-10"><title>Fitness assays evaluation</title><p>Competitive fitness assays of strains relative to a GFP-expressing reference <italic>K. quasipneumoniae</italic> FK688-GFP<sup>+</sup> strain were performed as described in <xref ref-type="bibr" rid="bib4">Barber et al., 2021</xref> with some modifications. Single colonies of ancestral, evolved, and reference strains were grown overnight at 37°C in 3 mL LB media (with and without antibiotic selection) with shaking in separate 15 mL falcon tubes. At saturation, the strain of interest and reference strain were mixed (100 μL:100 μL), diluted in PBS, and measured by fluorescence-activated cell sorting to determine the unadjusted proportions of the two strains. Based off these unadjusted values, volumes of experimental and reference strains were then modified to create a 1:1 cell density ratio, which is the initial starting frequency. The mixture of strains was then diluted 1:1000 (3 μL in 3 mL of LB) before propagating into fresh LB media each day (10 generations per day). 500 μL of sample was taken each day, diluted in 1×PBS (PBS [pH 7.4]: 137 mM NaCl, 2.7 mM KCl, 10 mM Na<sub>2</sub>HPO<sub>4</sub>, and 2 mM KH<sub>2</sub>PO<sub>4</sub>), and measured by flow cytometry (LSR Fortessa X20a) for the proportion of experimental to reference strains. A maximum total count of 50,000 events was used. The selection coefficient (S) per generation for each experimental strain relative to the reference strain was calculated by taking the natural logarithm of the ratio of experimental to reference strains at the initial and the final time point and dividing by the number of generations passed (<xref ref-type="bibr" rid="bib55">McDonald, 2019</xref>) as described by the following regression model formula:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mtext> </mml:mtext><mml:mi>S</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mi>ln</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">R</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>Where T=time (generations); E=frequency of evolved strain; <italic>R</italic>=frequency of the reference (GFP-labelled) strain; E<sub>t</sub>, R<sub>t</sub> = frequencies at time “t”; E<sub>0</sub>, R<sub>0</sub>=initial frequencies.</p><p>In other words, when S=0, the strains are equally fit; when S is positive, the evolved strain is more fit than the reference strain; and when S is negative, the evolved strain is less fit than the reference strain.</p><p>The relative fitness of the GFP-expressing FK688 strain is on average 0.040 for all experiments compared it to the ancestral FK688: Δ<italic>ompK36</italic> pNAR1strain with no GFP expression. The final selection coefficient of all graphs is calculated after normalising the relative fitness of the FK688-GFP<sup>+</sup> against the ancestor FK688.</p></sec><sec id="s4-11"><title>Evolution experiments</title><p>To set up the evolution experiment, single clones of the drug-resistant, non-functional porin (Δ<italic>ompK36</italic> pNAR1) strain and its homologous, membrane engineered (<italic>ompK36<sup>+</sup></italic>pNAR1) strain were used to seed 20 replicates each in 3 mL LB media and serially passaged in antibiotic-free media for 24 hr at 37°C with shaking in separate 15 mL falcon tubes. Every 24 hr, the populations were diluted 1:1000 (3 μL in 3 mL of LB), equating to roughly 10 generations per day. The strain populations were evolved for approximately 200 generations. The relative growth rate of all lineages and the parental strains was measured every 50 generations using fitness assays, and colony morphological features were assessed throughout the experiment. After 200 generations, four single clones of evolved strains with different morphological characteristics were selected for whole genome sequencing. After every 20 and 50 generations, 500 μL of evolved strains were mixed with 500 μL of 50% glycerol and stored at –80°C.</p></sec><sec id="s4-12"><title>Growth curves</title><p>Overnight bacterial cultures were subcultured 1:100 in CAMHB and grown until mid-log phase (OD<sub>600</sub> of 0.6–0.8). Cells were then diluted in CAMHB to an OD<sub>600</sub> of 0.05. Three biological replicates (each in technical replicates) were grown in a 96-well plate using the Tecan Spark 10 M. The plate was enclosed in a hydration chamber for 24 hr at 37°C with orbital shaking (200 rpm) amplitude 3 mm, and cell density (OD<sub>600</sub>) measurements were recorded every 60 min.</p></sec><sec id="s4-13"><title>Capsule polysaccharide analysis</title><p>Capsular polysaccharides of <italic>Klebsiella</italic> strains were extracted by the phenol-extraction method (<xref ref-type="bibr" rid="bib12">Campos et al., 2004</xref>) and quantified using colorimetric assays for glucuronic acid as previously described (<xref ref-type="bibr" rid="bib6">Blumenkrantz and Asboe-Hansen, 1973</xref>). Capsule extraction: overnight bacterial cultures were subcultured 1:50 in LB media and grown until the mid-log phase (OD600~0.4–0.6). Cells were collected by centrifugation (5000 × <italic>g</italic>, 15 min, 5°C), and the pellet was resuspended in 1 mL of dH2O. After centrifugation (14,000 × <italic>g</italic>, 10 min), the pellet was resuspended in 500 μl dH2O, and viable counts were determined. Samples were incubated at 68°C for 2 min, and 500 μL phenol (Sigma #P4557) was added and mixed by inversion. Following incubation at 68°C for 30 min, the mixture was cooled on ice for 2 min. 500 μL chloroform (Sigma-Aldrich #472476) was added, and the mixture was inverted. Samples were centrifuged (10,000 × <italic>g</italic>, 5 min), and approximately 400 μL of cell-free supernatant was mixed with 1 ml absolute ethanol, incubated at –20°C for 20 min, and washed with 70% ethanol. The carbohydrate-containing precipitate was resuspended in 500 μL dH2O. Samples were stored at 4°C. 200 μL of capsular material was mixed with 1.2 mL of 12.5 mM sodium tetraborate (Borax; NaBH4) in concentrated H<sub>2</sub>SO<sub>4</sub>. The mixtures were vigorously vortexed, boiled for 5 min, and then cooled on ice for 10 min before the addition of 20 μL of 0.15% 3-hydroxydiphenol in 0.5% NaOH. Absorbance was measured at 520 nm. A duplicate sample from each strain was prepared as described above but treated with 0.5% sodium hydroxide alone and used to measure the background absorbance at 520 nm. The glucuronic acid concentration in background-subtracted values for each sample was determined from a standard curve of <sub>D</sub>-Glucuronic acid.</p></sec><sec id="s4-14"><title>Phylogeny</title><p>377 complete <italic>Klebsiella</italic> genomes from the NCBI database were used to make a global phylogeny (downloaded May 2020). Roary (3.11.2; <xref ref-type="bibr" rid="bib63">Page et al., 2015</xref>) was used to align the genomes and extract the core genomes. The core genomes were used to generate a phylogenetical tree using RAxML v8.2.12 (<xref ref-type="bibr" rid="bib78">Stamatakis, 2014</xref>) with a general time reversible nucleotide substitution model with rate heterogeneity modelled with a gamma distribution (GTR +GAMMA). Branch supports were estimated using 1000 bootstrap replicates. Kleborate v0.3.0 (<xref ref-type="bibr" rid="bib89">Wyres et al., 2016</xref>) was used to identify MLST types. Perfect sequence matches of 7 MLST loci are indicated as ST and single- or double-locus variant of the exact ST is represented as STxx-1LV or STxx-2LV, respectively. Visualisation of the tree was generated with R using the package ggtree.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Investigation</p></fn><fn fn-type="con" id="con9"><p>Investigation</p></fn><fn fn-type="con" id="con10"><p>Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Investigation</p></fn><fn fn-type="con" id="con13"><p>Investigation</p></fn><fn fn-type="con" id="con14"><p>Investigation</p></fn><fn fn-type="con" id="con15"><p>Investigation</p></fn><fn fn-type="con" id="con16"><p>Investigation</p></fn><fn fn-type="con" id="con17"><p>Investigation</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Supervision, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83107-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Complete genome sequence data for <italic>Klebsiella quasipneumoniae</italic> subsp. <italic>similipneumoniae</italic> FK688 has been deposited at the NCBI (Accessions: CP072505, CP072506 and CP072507) and annotated through the Prokaryotic Genome Annotation Pipeline (PGAP) under the Bioproject PRJNA717371 and Biosample SAMN18498882.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Rosas</surname><given-names>NC</given-names></name><name><surname>Wilksch</surname><given-names>JJ</given-names></name><name><surname>Barber</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>The evolutionary mechanism of complex carbapenem-resistant phenotypes in Klebsiella spp</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA717371">PRJNA717371</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by the National Health and Medical Research Council (grant number 1092262) and a Monash BDI Postgraduate Research Scholarship.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Acosta-Gutiérrez</surname><given-names>S</given-names></name><name><surname>Ferrara</surname><given-names>L</given-names></name><name><surname>Pathania</surname><given-names>M</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bodrenko</surname><given-names>I</given-names></name><name><surname>Zahn</surname><given-names>M</given-names></name><name><surname>Winterhalter</surname><given-names>M</given-names></name><name><surname>Stavenger</surname><given-names>RA</given-names></name><name><surname>Pagès</surname><given-names>J-M</given-names></name><name><surname>Naismith</surname><given-names>JH</given-names></name><name><surname>van den Berg</surname><given-names>B</given-names></name><name><surname>Page</surname><given-names>MGP</given-names></name><name><surname>Ceccarelli</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Getting drugs into gram-negative bacteria: rational rules for permeation through general porins</article-title><source>ACS Infectious Diseases</source><volume>4</volume><fpage>1487</fpage><lpage>1498</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.8b00108</pub-id><pub-id pub-id-type="pmid">29962203</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Alcock</surname><given-names>BP</given-names></name><name><surname>Raphenya</surname><given-names>AR</given-names></name><name><surname>Lau</surname><given-names>TTY</given-names></name><name><surname>Tsang</surname><given-names>KK</given-names></name><name><surname>Bouchard</surname><given-names>M</given-names></name><name><surname>Edalatmand</surname><given-names>A</given-names></name><name><surname>Huynh</surname><given-names>W</given-names></name><name><surname>Nguyen</surname><given-names>AV</given-names></name><name><surname>Cheng</surname><given-names>AA</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Min</surname><given-names>SY</given-names></name><name><surname>Miroshnichenko</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Werfalli</surname><given-names>RE</given-names></name><name><surname>Nasir</surname><given-names>JA</given-names></name><name><surname>Oloni</surname><given-names>M</given-names></name><name><surname>Speicher</surname><given-names>DJ</given-names></name><name><surname>Florescu</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>B</given-names></name><name><surname>Faltyn</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>KA</given-names></name><name><surname>Sharma</surname><given-names>AN</given-names></name><name><surname>Bordeleau</surname><given-names>E</given-names></name><name><surname>Pawlowski</surname><given-names>AC</given-names></name><name><surname>Zubyk</surname><given-names>HL</given-names></name><name><surname>Dooley</surname><given-names>D</given-names></name><name><surname>Griffiths</surname><given-names>E</given-names></name><name><surname>Maguire</surname><given-names>F</given-names></name><name><surname>Winsor</surname><given-names>GL</given-names></name><name><surname>Beiko</surname><given-names>RG</given-names></name><name><surname>Brinkman</surname><given-names>FSL</given-names></name><name><surname>Hsiao</surname><given-names>WWL</given-names></name><name><surname>Domselaar</surname><given-names>GV</given-names></name><name><surname>McArthur</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>The resistance gene Identifier (RGI)</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/arpcard/rgi">https://github.com/arpcard/rgi</ext-link></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Ara</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>Y</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Datsenko</surname><given-names>KA</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Wanner</surname><given-names>BL</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Construction of <italic>Escherichia coli</italic> K-12 in-frame, single-gene knockout mutants: The Keio collection</article-title><source>Molecular Systems Biology</source><volume>2</volume><elocation-id>2006.0008</elocation-id><pub-id pub-id-type="doi">10.1038/msb4100050</pub-id><pub-id pub-id-type="pmid">16738554</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>JN</given-names></name><name><surname>Sezmis</surname><given-names>AL</given-names></name><name><surname>Woods</surname><given-names>LC</given-names></name><name><surname>Anderson</surname><given-names>TD</given-names></name><name><surname>Voss</surname><given-names>JM</given-names></name><name><surname>McDonald</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The evolution of coexistence from competition in experimental co-cultures of <italic>Escherichia coli</italic> and <italic>Saccharomyces cerevisiae</italic></article-title><source>The ISME Journal</source><volume>15</volume><fpage>746</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1038/s41396-020-00810-z</pub-id><pub-id pub-id-type="pmid">33093620</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Dunstan</surname><given-names>RA</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Torres</surname><given-names>VVL</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wilksch</surname><given-names>JJ</given-names></name><name><surname>Strugnell</surname><given-names>RA</given-names></name><name><surname>Lithgow</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Extensively drug-resistant <italic>Klebsiella pneumoniae</italic> causing nosocomial bloodstream infections in China: molecular investigation of antibiotic resistance determinants, informing therapy, and clinical outcomes</article-title><source>Frontiers in Microbiology</source><volume>8</volume><elocation-id>1230</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.01230</pub-id><pub-id pub-id-type="pmid">28713357</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenkrantz</surname><given-names>N</given-names></name><name><surname>Asboe-Hansen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>New method for quantitative determination of uronic acids</article-title><source>Analytical Biochemistry</source><volume>54</volume><fpage>484</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(73)90377-1</pub-id><pub-id pub-id-type="pmid">4269305</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Trimmomatic</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/timflutre/trimmomatic">https://github.com/timflutre/trimmomatic</ext-link></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouganim</surname><given-names>R</given-names></name><name><surname>Dykman</surname><given-names>L</given-names></name><name><surname>Fakeh</surname><given-names>O</given-names></name><name><surname>Motro</surname><given-names>Y</given-names></name><name><surname>Oren</surname><given-names>R</given-names></name><name><surname>Daniel</surname><given-names>C</given-names></name><name><surname>Lazarovitch</surname><given-names>T</given-names></name><name><surname>Zaidenstein</surname><given-names>R</given-names></name><name><surname>Moran-Gilad</surname><given-names>J</given-names></name><name><surname>Marchaim</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The clinical and molecular epidemiology of noncarbapenemase-producing carbapenem-resistant <italic>Enterobacteriaceae</italic>: A case-case-control matched analysis</article-title><source>Open Forum Infectious Diseases</source><volume>7</volume><elocation-id>ofaa299</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofaa299</pub-id><pub-id pub-id-type="pmid">32855986</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowers</surname><given-names>JR</given-names></name><name><surname>Kitchel</surname><given-names>B</given-names></name><name><surname>Driebe</surname><given-names>EM</given-names></name><name><surname>MacCannell</surname><given-names>DR</given-names></name><name><surname>Roe</surname><given-names>C</given-names></name><name><surname>Lemmer</surname><given-names>D</given-names></name><name><surname>de Man</surname><given-names>T</given-names></name><name><surname>Rasheed</surname><given-names>JK</given-names></name><name><surname>Engelthaler</surname><given-names>DM</given-names></name><name><surname>Keim</surname><given-names>P</given-names></name><name><surname>Limbago</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genomic analysis of the emergence and rapid global dissemination of the clonal group 258 Klebsiella pneumoniae pandemic</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0133727</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0133727</pub-id><pub-id pub-id-type="pmid">26196384</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brisse</surname><given-names>S</given-names></name><name><surname>Passet</surname><given-names>V</given-names></name><name><surname>Grimont</surname><given-names>PAD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Description of Klebsiella quasipneumoniae sp. nov., isolated from human infections, with two subspecies, Klebsiella quasipneumoniae subsp. quasipneumoniae subsp. nov. and Klebsiella quasipneumoniae subsp. similipneumoniae subsp. nov., and demonstration that Klebsiella singaporensis is a junior heterotypic synonym of Klebsiella variicola</article-title><source>International Journal of Systematic and Evolutionary Microbiology</source><volume>64</volume><fpage>3146</fpage><lpage>3152</lpage><pub-id pub-id-type="doi">10.1099/ijs.0.062737-0</pub-id><pub-id pub-id-type="pmid">24958762</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>DWA</given-names></name><name><surname>Jones</surname><given-names>DT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The PSIPRED protein analysis workbench: 20 years on</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W402</fpage><lpage>W407</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz297</pub-id><pub-id pub-id-type="pmid">31251384</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>MA</given-names></name><name><surname>Vargas</surname><given-names>MA</given-names></name><name><surname>Regueiro</surname><given-names>V</given-names></name><name><surname>Llompart</surname><given-names>CM</given-names></name><name><surname>Albertí</surname><given-names>S</given-names></name><name><surname>Bengoechea</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides</article-title><source>Infection and Immunity</source><volume>72</volume><fpage>7107</fpage><lpage>7114</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.12.7107-7114.2004</pub-id><pub-id pub-id-type="pmid">15557634</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carver</surname><given-names>T</given-names></name><name><surname>Thomson</surname><given-names>N</given-names></name><name><surname>Bleasby</surname><given-names>A</given-names></name><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Parkhill</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>DNAPlotter: circular and linear interactive genome visualization</article-title><source>Bioinformatics</source><volume>25</volume><fpage>119</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btn578</pub-id><pub-id pub-id-type="pmid">18990721</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherepanov</surname><given-names>PP</given-names></name><name><surname>Wackernagel</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Gene disruption in <italic>Escherichia coli</italic>: TcR and KmR cassettes with the option of FLP-catalyzed excision of the antibiotic-resistance determinant</article-title><source>Gene</source><volume>158</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(95)00193-a</pub-id><pub-id pub-id-type="pmid">7789817</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="book"><person-group person-group-type="author"><collab>CLSI</collab></person-group><year iso-8601-date="2015">2015</year><source>Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard</source><publisher-name>Clinical and Laboratory Standards Institute</publisher-name></element-citation></ref><ref id="bib16"><element-citation publication-type="book"><person-group person-group-type="author"><collab>CLSI</collab></person-group><year iso-8601-date="2022">2022</year><source>Performance Standards for Antimicrobial Susceptibility Testing</source><publisher-name>Clinical and Laboratory Standards Institute</publisher-name></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codjoe</surname><given-names>FS</given-names></name><name><surname>Donkor</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Carbapenem resistance: A review</article-title><source>Medical Sciences</source><volume>6</volume><elocation-id>1</elocation-id><pub-id pub-id-type="doi">10.3390/medsci6010001</pub-id><pub-id pub-id-type="pmid">29267233</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datsenko</surname><given-names>KA</given-names></name><name><surname>Wanner</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>One-step inactivation of chromosomal genes in <italic>Escherichia coli</italic> K-12 using PCR products</article-title><source>PNAS</source><volume>97</volume><fpage>6640</fpage><lpage>6645</lpage><pub-id pub-id-type="doi">10.1073/pnas.120163297</pub-id><pub-id pub-id-type="pmid">10829079</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DelaVega</surname><given-names>AL</given-names></name><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Cadaverine induces closing of <italic>E. coli</italic> porins</article-title><source>The EMBO Journal</source><volume>14</volume><fpage>6058</fpage><lpage>6065</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1995.tb00294.x</pub-id><pub-id pub-id-type="pmid">8846798</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dela Vega</surname><given-names>AL</given-names></name><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Polyamines decrease <italic>Escherichia coli</italic> outer membrane permeability</article-title><source>Journal of Bacteriology</source><volume>178</volume><fpage>3715</fpage><lpage>3721</lpage><pub-id pub-id-type="doi">10.1128/jb.178.13.3715-3721.1996</pub-id><pub-id pub-id-type="pmid">8682771</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Carbapenemase-producing Enterobacteriaceae</article-title><source>Seminars in Respiratory and Critical Care Medicine</source><volume>36</volume><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1055/s-0035-1544208</pub-id><pub-id pub-id-type="pmid">25643272</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Treatment options for Carbapenem-resistant gram-negative bacterial infections</article-title><source>Clinical Infectious Diseases</source><volume>69</volume><fpage>S565</fpage><lpage>S575</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz830</pub-id><pub-id pub-id-type="pmid">31724043</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunstan</surname><given-names>RA</given-names></name><name><surname>Hay</surname><given-names>ID</given-names></name><name><surname>Lithgow</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining membrane protein localization by Isopycnic density gradients</article-title><source>Methods in Molecular Biology</source><volume>1615</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7033-9_6</pub-id><pub-id pub-id-type="pmid">28667604</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Ganesamoorthy</surname><given-names>D</given-names></name><name><surname>Coin</surname><given-names>L</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Cao</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Complete genome sequence of Klebsiella quasipneumoniae subsp. similipneumoniae strain ATCC 700603</source><publisher-name>Genome Announcements</publisher-name><volume>4</volume><pub-id pub-id-type="doi">10.1128/genomeA.00438-16</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elshamy</surname><given-names>AA</given-names></name><name><surname>Aboshanab</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A review on bacterial resistance to Carbapenems: epidemiology, detection and treatment options</article-title><source>Future Science OA</source><volume>6</volume><elocation-id>FSO438</elocation-id><pub-id pub-id-type="doi">10.2144/fsoa-2019-0098</pub-id><pub-id pub-id-type="pmid">32140243</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fevre</surname><given-names>C</given-names></name><name><surname>Passet</surname><given-names>V</given-names></name><name><surname>Weill</surname><given-names>FX</given-names></name><name><surname>Grimont</surname><given-names>PAD</given-names></name><name><surname>Brisse</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Variants of the Klebsiella pneumoniae OKP chromosomal beta-lactamase are divided into two main groups, OKP-A and OKP-B</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>49</volume><fpage>5149</fpage><lpage>5152</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.12.5149-5152.2005</pub-id><pub-id pub-id-type="pmid">16304190</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flach</surname><given-names>C-F</given-names></name><name><surname>Pal</surname><given-names>C</given-names></name><name><surname>Svensson</surname><given-names>CJ</given-names></name><name><surname>Kristiansson</surname><given-names>E</given-names></name><name><surname>Östman</surname><given-names>M</given-names></name><name><surname>Bengtsson-Palme</surname><given-names>J</given-names></name><name><surname>Tysklind</surname><given-names>M</given-names></name><name><surname>Larsson</surname><given-names>DGJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Does antifouling paint select for antibiotic resistance</article-title><source>The Science of the Total Environment</source><volume>590–591</volume><fpage>461</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1016/j.scitotenv.2017.01.213</pub-id><pub-id pub-id-type="pmid">28284638</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geer</surname><given-names>LY</given-names></name><name><surname>Domrachev</surname><given-names>M</given-names></name><name><surname>Lipman</surname><given-names>DJ</given-names></name><name><surname>Bryant</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>CDART: protein homology by domain architecture</article-title><source>Genome Research</source><volume>12</volume><fpage>1619</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1101/gr.278202</pub-id><pub-id pub-id-type="pmid">12368255</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacobbe</surname><given-names>DR</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>De Rosa</surname><given-names>FG</given-names></name><name><surname>Del Bono</surname><given-names>V</given-names></name><name><surname>Grossi</surname><given-names>PA</given-names></name><name><surname>Menichetti</surname><given-names>F</given-names></name><name><surname>Pea</surname><given-names>F</given-names></name><name><surname>Rossolini</surname><given-names>GM</given-names></name><name><surname>Tumbarello</surname><given-names>M</given-names></name><name><surname>Viale</surname><given-names>P</given-names></name><name><surname>Viscoli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ceftolozane/Tazobactam: place in therapy</article-title><source>Expert Review of Anti-Infective Therapy</source><volume>16</volume><fpage>307</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1080/14787210.2018.1447381</pub-id><pub-id pub-id-type="pmid">29493397</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>KE</given-names></name><name><surname>Simner</surname><given-names>PJ</given-names></name><name><surname>Tamma</surname><given-names>PD</given-names></name><name><surname>Milstone</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Infection control implications of heterogeneous resistance mechanisms in Carbapenem-resistant Enterobacteriaceae</article-title><source>Expert Review of Anti-Infective Therapy</source><volume>14</volume><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1586/14787210.2016.1106940</pub-id><pub-id pub-id-type="pmid">26535959</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordillo Altamirano</surname><given-names>FL</given-names></name><name><surname>Barr</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Unlocking the next generation of phage therapy: the key is in the receptors</article-title><source>Current Opinion in Biotechnology</source><volume>68</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2020.10.002</pub-id><pub-id pub-id-type="pmid">33202354</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gordillo Altamirano</surname><given-names>F</given-names></name><name><surname>Forsyth</surname><given-names>JH</given-names></name><name><surname>Patwa</surname><given-names>R</given-names></name><name><surname>Kostoulias</surname><given-names>X</given-names></name><name><surname>Trim</surname><given-names>M</given-names></name><name><surname>Subedi</surname><given-names>D</given-names></name><name><surname>Archer</surname><given-names>SK</given-names></name><name><surname>Morris</surname><given-names>FC</given-names></name><name><surname>Oliveira</surname><given-names>C</given-names></name><name><surname>Kielty</surname><given-names>L</given-names></name><name><surname>Korneev</surname><given-names>D</given-names></name><name><surname>O’Bryan</surname><given-names>MK</given-names></name><name><surname>Lithgow</surname><given-names>TJ</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Barr</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Bacteriophage-resistant <italic>Acinetobacter baumannii</italic> are resensitized to antimicrobials</article-title><source>Nature Microbiology</source><volume>6</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00830-7</pub-id><pub-id pub-id-type="pmid">33432151</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Halat</surname><given-names>DH</given-names></name><name><surname>Sarkis</surname><given-names>DK</given-names></name><name><surname>Moubareck</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><source>Antibiotic Resistance</source><publisher-name>Academic Press</publisher-name></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>GT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Continuous evolution: perspective on the epidemiology of Carbapenemase resistance among Enterobacterales and other gram-negative bacteria</article-title><source>Infectious Diseases and Therapy</source><volume>10</volume><fpage>75</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/s40121-020-00395-2</pub-id><pub-id pub-id-type="pmid">33492641</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardiman</surname><given-names>CA</given-names></name><name><surname>Weingarten</surname><given-names>RA</given-names></name><name><surname>Conlan</surname><given-names>S</given-names></name><name><surname>Khil</surname><given-names>P</given-names></name><name><surname>Dekker</surname><given-names>JP</given-names></name><name><surname>Mathers</surname><given-names>AJ</given-names></name><name><surname>Sheppard</surname><given-names>AE</given-names></name><name><surname>Segre</surname><given-names>JA</given-names></name><name><surname>Frank</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Horizontal transfer of Carbapenemase-Encoding Plasmids and comparison with hospital epidemiology data</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>60</volume><fpage>4910</fpage><lpage>4919</lpage><pub-id pub-id-type="doi">10.1128/AAC.00014-16</pub-id><pub-id pub-id-type="pmid">27270289</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>PNA</given-names></name><name><surname>Tambyah</surname><given-names>PA</given-names></name><name><surname>Lye</surname><given-names>DC</given-names></name><name><surname>Mo</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Yilmaz</surname><given-names>M</given-names></name><name><surname>Alenazi</surname><given-names>TH</given-names></name><name><surname>Arabi</surname><given-names>Y</given-names></name><name><surname>Falcone</surname><given-names>M</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Righi</surname><given-names>E</given-names></name><name><surname>Rogers</surname><given-names>BA</given-names></name><name><surname>Kanj</surname><given-names>S</given-names></name><name><surname>Bhally</surname><given-names>H</given-names></name><name><surname>Iredell</surname><given-names>J</given-names></name><name><surname>Mendelson</surname><given-names>M</given-names></name><name><surname>Boyles</surname><given-names>TH</given-names></name><name><surname>Looke</surname><given-names>D</given-names></name><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Walls</surname><given-names>G</given-names></name><name><surname>Al Khamis</surname><given-names>M</given-names></name><name><surname>Zikri</surname><given-names>A</given-names></name><name><surname>Crowe</surname><given-names>A</given-names></name><name><surname>Ingram</surname><given-names>P</given-names></name><name><surname>Daneman</surname><given-names>N</given-names></name><name><surname>Griffin</surname><given-names>P</given-names></name><name><surname>Athan</surname><given-names>E</given-names></name><name><surname>Lorenc</surname><given-names>P</given-names></name><name><surname>Baker</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>L</given-names></name><name><surname>Beatson</surname><given-names>SA</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Harris-Brown</surname><given-names>T</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effect of piperacillin-Tazobactam vs Meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and Ceftriaxone resistance: A randomized clinical trial</article-title><source>JAMA</source><volume>320</volume><fpage>984</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.12163</pub-id><pub-id pub-id-type="pmid">30208454</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennequin</surname><given-names>C</given-names></name><name><surname>Robin</surname><given-names>F</given-names></name><name><surname>Cabrolier</surname><given-names>N</given-names></name><name><surname>Bonnet</surname><given-names>R</given-names></name><name><surname>Forestier</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Characterization of a DHA-1-producing <italic>Klebsiella pneumoniae</italic> strain involved in an outbreak and role of the AmpR regulator in virulence</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>56</volume><fpage>288</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1128/AAC.00164-11</pub-id><pub-id pub-id-type="pmid">21986829</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herring</surname><given-names>CD</given-names></name><name><surname>Glasner</surname><given-names>JD</given-names></name><name><surname>Blattner</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Gene replacement without selection: regulated suppression of amber mutations in <italic>Escherichia coli</italic></article-title><source>Gene</source><volume>311</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/s0378-1119(03)00585-7</pub-id><pub-id pub-id-type="pmid">12853150</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Yoon</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Jeong</surname><given-names>SH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Performance evaluation of the PANA Realtyper CRE kit for detecting Carbapenemase genes in gram-negative bacilli</article-title><source>Journal of Global Antimicrobial Resistance</source><volume>18</volume><fpage>100</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.jgar.2019.02.002</pub-id><pub-id pub-id-type="pmid">30763759</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>F-P</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>D-M</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Jiang</surname><given-names>X-F</given-names></name><name><surname>Xu</surname><given-names>Y-C</given-names></name><name><surname>Zhang</surname><given-names>X-J</given-names></name><name><surname>Zhang</surname><given-names>C-X</given-names></name><name><surname>Ji</surname><given-names>P</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C-Q</given-names></name><name><surname>Wang</surname><given-names>A-M</given-names></name><name><surname>Xu</surname><given-names>Y-H</given-names></name><name><surname>Shen</surname><given-names>J-L</given-names></name><name><surname>Sun</surname><given-names>Z-Y</given-names></name><name><surname>Chen</surname><given-names>Z-J</given-names></name><name><surname>Ni</surname><given-names>Y-X</given-names></name><name><surname>Sun</surname><given-names>J-Y</given-names></name><name><surname>Chu</surname><given-names>Y-Z</given-names></name><name><surname>Tian</surname><given-names>S-F</given-names></name><name><surname>Hu</surname><given-names>Z-D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Y-S</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>L-H</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y-J</given-names></name><name><surname>Ai</surname><given-names>X-M</given-names></name><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>D-H</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Jia</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014</article-title><source>Clinical Microbiology and Infection</source><volume>22 Suppl 1</volume><fpage>S9</fpage><lpage>S14</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.01.001</pub-id><pub-id pub-id-type="pmid">27000156</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iyer</surname><given-names>R</given-names></name><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Complex inhibition of OmpF and OmpC bacterial porins by polyamines</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>18595</fpage><lpage>18601</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.30.18595</pub-id><pub-id pub-id-type="pmid">9228026</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>AU</given-names></name><name><surname>Maryam</surname><given-names>L</given-names></name><name><surname>Zarrilli</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure, genetics and worldwide spread of new Delhi Metallo-beta-lactamase (NDM): a threat to public health</article-title><source>BMC Microbiology</source><volume>17</volume><elocation-id>101</elocation-id><pub-id pub-id-type="doi">10.1186/s12866-017-1012-8</pub-id><pub-id pub-id-type="pmid">28449650</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitchel</surname><given-names>B</given-names></name><name><surname>Rasheed</surname><given-names>JK</given-names></name><name><surname>Patel</surname><given-names>JB</given-names></name><name><surname>Srinivasan</surname><given-names>A</given-names></name><name><surname>Navon-Venezia</surname><given-names>S</given-names></name><name><surname>Carmeli</surname><given-names>Y</given-names></name><name><surname>Brolund</surname><given-names>A</given-names></name><name><surname>Giske</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: Clonal expansion of multilocus sequence type 258</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>53</volume><fpage>3365</fpage><lpage>3370</lpage><pub-id pub-id-type="doi">10.1128/AAC.00126-09</pub-id><pub-id pub-id-type="pmid">19506063</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klemm</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Two regulatory fim genes, fimB and fimE, control the phase variation of type 1 fimbriae in <italic>Escherichia coli</italic></article-title><source>The EMBO Journal</source><volume>5</volume><fpage>1389</fpage><lpage>1393</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1986.tb04372.x</pub-id><pub-id pub-id-type="pmid">2874022</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Koren S</surname><given-names>S</given-names></name><name><surname>Walenz</surname><given-names>BP</given-names></name><name><surname>Berlin</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>JR</given-names></name><name><surname>Phillippy</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Canu</data-title><version designator="v1.8">v1.8</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/marbl/canu">https://github.com/marbl/canu</ext-link></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuchibiro</surname><given-names>T</given-names></name><name><surname>Komatsu</surname><given-names>M</given-names></name><name><surname>Yamasaki</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nishio</surname><given-names>H</given-names></name><name><surname>Nishi</surname><given-names>I</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Niki</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>T</given-names></name><name><surname>Sueyoshi</surname><given-names>N</given-names></name><name><surname>Kita</surname><given-names>M</given-names></name><name><surname>Kida</surname><given-names>K</given-names></name><name><surname>Ohama</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>K</given-names></name><name><surname>Toda</surname><given-names>H</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>N</given-names></name><name><surname>Sawa</surname><given-names>K</given-names></name><name><surname>Nakai</surname><given-names>I</given-names></name><name><surname>Kofuku</surname><given-names>T</given-names></name><name><surname>Orita</surname><given-names>T</given-names></name><name><surname>Watari</surname><given-names>H</given-names></name><name><surname>Shimura</surname><given-names>S</given-names></name><name><surname>Fukuda</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluation of the modified Carbapenem inactivation method for the detection of Carbapenemase-producing Enterobacteriaceae</article-title><source>Journal of Infection and Chemotherapy</source><volume>24</volume><fpage>262</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2017.11.010</pub-id><pub-id pub-id-type="pmid">29248418</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DJ</given-names></name><name><surname>Bingle</surname><given-names>LEH</given-names></name><name><surname>Heurlier</surname><given-names>K</given-names></name><name><surname>Pallen</surname><given-names>MJ</given-names></name><name><surname>Penn</surname><given-names>CW</given-names></name><name><surname>Busby</surname><given-names>SJW</given-names></name><name><surname>Hobman</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Gene doctoring: a method for recombineering in laboratory and pathogenic <italic>Escherichia coli</italic> strains</article-title><source>BMC Microbiology</source><volume>9</volume><elocation-id>252</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2180-9-252</pub-id><pub-id pub-id-type="pmid">20003185</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>LK</given-names></name><name><surname>Weinstein</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The epidemiology of Carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace</article-title><source>The Journal of Infectious Diseases</source><volume>215</volume><fpage>S28</fpage><lpage>S36</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw282</pub-id><pub-id pub-id-type="pmid">28375512</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>SW</given-names></name><name><surname>Linson</surname><given-names>SE</given-names></name><name><surname>Ojeda Saavedra</surname><given-names>M</given-names></name><name><surname>Cantu</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>JJ</given-names></name><name><surname>Brettin</surname><given-names>T</given-names></name><name><surname>Olsen</surname><given-names>RJ</given-names></name><name><surname>D’Orazio</surname><given-names>SEF</given-names></name><name><surname>Doern</surname><given-names>C</given-names></name><name><surname>Burnham</surname><given-names>CAD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Whole-genome sequencing of human clinical <italic>Klebsiella pneumoniae</italic> isolates reveals misidentification and misunderstandings of <italic>Klebsiella pneumoniae</italic>, <italic>Klebsiella variicola</italic>, and <italic>Klebsiella quasipneumoniae</italic></article-title><source>MSphere</source><volume>2</volume><elocation-id>00290-17</elocation-id><pub-id pub-id-type="doi">10.1128/mSphereDirect.00290-17</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>YM</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Buso</surname><given-names>N</given-names></name><name><surname>Gur</surname><given-names>T</given-names></name><name><surname>Madhusoodanan</surname><given-names>N</given-names></name><name><surname>Basutkar</surname><given-names>P</given-names></name><name><surname>Tivey</surname><given-names>ARN</given-names></name><name><surname>Potter</surname><given-names>SC</given-names></name><name><surname>Finn</surname><given-names>RD</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The EMBL-EBI search and sequence analysis tools Apis in 2019</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>W636</fpage><lpage>W641</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz268</pub-id><pub-id pub-id-type="pmid">30976793</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Martínez</surname><given-names>L</given-names></name><name><surname>Hernández-Allés</surname><given-names>S</given-names></name><name><surname>Albertí</surname><given-names>S</given-names></name><name><surname>Tomás</surname><given-names>JM</given-names></name><name><surname>Benedi</surname><given-names>VJ</given-names></name><name><surname>Jacoby</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>40</volume><fpage>342</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1128/AAC.40.2.342</pub-id><pub-id pub-id-type="pmid">8834877</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mata</surname><given-names>MT</given-names></name><name><surname>Baquero</surname><given-names>F</given-names></name><name><surname>Pérez-Díaz</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A multidrug efflux transporter in Listeria monocytogenes</article-title><source>FEMS Microbiology Letters</source><volume>187</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2000.tb09158.x</pub-id><pub-id pub-id-type="pmid">10856655</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matatov</surname><given-names>R</given-names></name><name><surname>Goldhar</surname><given-names>J</given-names></name><name><surname>Skutelsky</surname><given-names>E</given-names></name><name><surname>Sechter</surname><given-names>I</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Podschun</surname><given-names>R</given-names></name><name><surname>Sahly</surname><given-names>H</given-names></name><name><surname>Thankavel</surname><given-names>K</given-names></name><name><surname>Abraham</surname><given-names>SN</given-names></name><name><surname>Ofek</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Inability of encapsulated Klebsiella pneumoniae to assemble functional type 1 fimbriae on their surface</article-title><source>FEMS Microbiology Letters</source><volume>179</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.1999.tb08717.x</pub-id><pub-id pub-id-type="pmid">10481096</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>AJ</given-names></name><name><surname>Crook</surname><given-names>D</given-names></name><name><surname>Vaughan</surname><given-names>A</given-names></name><name><surname>Barry</surname><given-names>KE</given-names></name><name><surname>Vegesana</surname><given-names>K</given-names></name><name><surname>Stoesser</surname><given-names>N</given-names></name><name><surname>Parikh</surname><given-names>HI</given-names></name><name><surname>Sebra</surname><given-names>R</given-names></name><name><surname>Kotay</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>AS</given-names></name><name><surname>Sheppard</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title><italic>Klebsiella Quasipneumoniae</italic> provides a window into Carbapenemase gene transfer, plasmid rearrangements, and patient interactions with the hospital environment</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>63</volume><elocation-id>e02513-18</elocation-id><pub-id pub-id-type="doi">10.1128/AAC.02513-18</pub-id><pub-id pub-id-type="pmid">30910889</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Microbial experimental evolution - a proving ground for evolutionary theory and a tool for discovery</article-title><source>EMBO Reports</source><volume>20</volume><elocation-id>e46992</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201846992</pub-id><pub-id pub-id-type="pmid">31338963</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meletis</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Carbapenem resistance: overview of the problem and future perspectives</article-title><source>Therapeutic Advances in Infectious Disease</source><volume>3</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1177/2049936115621709</pub-id><pub-id pub-id-type="pmid">26862399</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meunier</surname><given-names>D</given-names></name><name><surname>Woodford</surname><given-names>N</given-names></name><name><surname>Hopkins</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Evaluation of the AusDiagnostics MT CRE EU assay for the detection of carbapenemase genes and transferable colistin resistance determinants <italic>mcr-1/-2</italic> in MDR Gram-negative bacteria</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>73</volume><fpage>3355</fpage><lpage>3358</lpage><pub-id pub-id-type="doi">10.1093/jac/dky347</pub-id><pub-id pub-id-type="pmid">30189011</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolas-Chanoine</surname><given-names>M-H</given-names></name><name><surname>Mayer</surname><given-names>N</given-names></name><name><surname>Guyot</surname><given-names>K</given-names></name><name><surname>Dumont</surname><given-names>E</given-names></name><name><surname>Pagès</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interplay between membrane permeability and enzymatic barrier leads to antibiotic-dependent resistance in <italic>Klebsiella pneumoniae</italic></article-title><source>Frontiers in Microbiology</source><volume>9</volume><elocation-id>1422</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.01422</pub-id><pub-id pub-id-type="pmid">30008709</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Kuronishi</surname><given-names>M</given-names></name><name><surname>Uehara</surname><given-names>H</given-names></name><name><surname>Ogata</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ViPTree: the viral proteomic tree server</article-title><source>Bioinformatics</source><volume>33</volume><fpage>2379</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx157</pub-id><pub-id pub-id-type="pmid">28379287</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordmann</surname><given-names>P</given-names></name><name><surname>Poirel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epidemiology and diagnostics of Carbapenem resistance in Gram-negative bacteria</article-title><source>Clinical Infectious Diseases</source><volume>69</volume><fpage>S521</fpage><lpage>S528</lpage><pub-id pub-id-type="doi">10.1093/cid/ciz824</pub-id><pub-id pub-id-type="pmid">31724045</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Octavia</surname><given-names>S</given-names></name><name><surname>Kalisvar</surname><given-names>M</given-names></name><name><surname>Venkatachalam</surname><given-names>I</given-names></name><name><surname>Ng</surname><given-names>OT</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Sridatta</surname><given-names>PSR</given-names></name><name><surname>Ong</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>LD</given-names></name><name><surname>Chua</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>RTP</given-names></name><name><surname>Teo</surname><given-names>JWP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Klebsiella pneumoniae and <italic>Klebsiella quasipneumoniae</italic> define the population structure of blaKPC-2Klebsiella: a 5 year retrospective Genomic study in Singapore</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>74</volume><fpage>3205</fpage><lpage>3210</lpage><pub-id pub-id-type="doi">10.1093/jac/dkz332</pub-id><pub-id pub-id-type="pmid">31504571</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortiz-Suarez</surname><given-names>ML</given-names></name><name><surname>Samsudin</surname><given-names>F</given-names></name><name><surname>Piggot</surname><given-names>TJ</given-names></name><name><surname>Bond</surname><given-names>PJ</given-names></name><name><surname>Khalid</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Full-length OmpA: structure, function, and membrane interactions predicted by molecular dynamics simulations</article-title><source>Biophysical Journal</source><volume>111</volume><fpage>1692</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2016.09.009</pub-id><pub-id pub-id-type="pmid">27760356</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>AJ</given-names></name><name><surname>Cummins</surname><given-names>CA</given-names></name><name><surname>Hunt</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>VK</given-names></name><name><surname>Reuter</surname><given-names>S</given-names></name><name><surname>Holden</surname><given-names>MTG</given-names></name><name><surname>Fookes</surname><given-names>M</given-names></name><name><surname>Falush</surname><given-names>D</given-names></name><name><surname>Keane</surname><given-names>JA</given-names></name><name><surname>Parkhill</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Roary: rapid large-scale prokaryote pan genome analysis</article-title><source>Bioinformatics</source><volume>31</volume><fpage>3691</fpage><lpage>3693</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv421</pub-id><pub-id pub-id-type="pmid">26198102</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrella</surname><given-names>S</given-names></name><name><surname>Ziental-Gelus</surname><given-names>N</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Renard</surname><given-names>M</given-names></name><name><surname>Jarlier</surname><given-names>V</given-names></name><name><surname>Sougakoff</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an <italic>Escherichia coli</italic> strain and an Enterobacter cloacae strain isolated from the same patient in France</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>52</volume><fpage>3725</fpage><lpage>3736</lpage><pub-id pub-id-type="doi">10.1128/AAC.00163-08</pub-id><pub-id pub-id-type="pmid">18625772</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>EA</given-names></name><name><surname>Haslam</surname><given-names>D</given-names></name><name><surname>Mortensen</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Performance of the check-points check-MDR CT103Xl assay utilizing the CDC/FDA antimicrobial resistance isolate bank</article-title><source>Diagnostic Microbiology and Infectious Disease</source><volume>88</volume><fpage>219</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2017.04.011</pub-id><pub-id pub-id-type="pmid">28502397</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>RP</given-names></name><name><surname>Urban</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns</article-title><source>Pharmacotherapy</source><volume>32</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.2012.01035.x</pub-id><pub-id pub-id-type="pmid">22488420</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Realegeno</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>K</given-names></name><name><surname>Garner</surname><given-names>OB</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Deceiving Phenotypic susceptibility results on a Klebsiella pneumoniae blood isolate carrying plasmid-mediated AmpC gene <sup>bla</sup> DHA-1</article-title><source>Frontiers in Cellular and Infection Microbiology</source><volume>11</volume><elocation-id>561880</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.561880</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revez</surname><given-names>J</given-names></name><name><surname>Espinosa</surname><given-names>L</given-names></name><name><surname>Albiger</surname><given-names>B</given-names></name><name><surname>Leitmeyer</surname><given-names>KC</given-names></name><name><surname>Struelens</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Survey on the use of whole-genome sequencing for infectious diseases surveillance: rapid expansion of European national capacities, 2015-2016</article-title><source>Frontiers in Public Health</source><volume>5</volume><elocation-id>347</elocation-id><pub-id pub-id-type="doi">10.3389/fpubh.2017.00347</pub-id><pub-id pub-id-type="pmid">29326921</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>S</given-names></name><name><surname>Nicolau</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Precision medicine for the diagnosis and treatment of Carbapenem-resistant Enterobacterales: time to think from a different perspective</article-title><source>Expert Review of Anti-Infective Therapy</source><volume>18</volume><fpage>721</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1760844</pub-id><pub-id pub-id-type="pmid">32368940</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocker</surname><given-names>A</given-names></name><name><surname>Lacey</surname><given-names>JA</given-names></name><name><surname>Belousoff</surname><given-names>MJ</given-names></name><name><surname>Wilksch</surname><given-names>JJ</given-names></name><name><surname>Strugnell</surname><given-names>RA</given-names></name><name><surname>Davies</surname><given-names>MR</given-names></name><name><surname>Lithgow</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Global trends in proteome remodeling of the outer membrane modulate antimicrobial permeability in Klebsiella pneumoniae</article-title><source>MBio</source><volume>11</volume><elocation-id>e00603-20</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00603-20</pub-id><pub-id pub-id-type="pmid">32291303</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>C</given-names></name><name><surname>Passet</surname><given-names>V</given-names></name><name><surname>Rakotondrasoa</surname><given-names>A</given-names></name><name><surname>Diallo</surname><given-names>TA</given-names></name><name><surname>Criscuolo</surname><given-names>A</given-names></name><name><surname>Brisse</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Description of Klebsiella africanensis sp. nov., Klebsiella variicola subsp. tropicalensis subsp. nov. and Klebsiella variicola subsp. variicola subsp. nov</article-title><source>Research in Microbiology</source><volume>170</volume><elocation-id>300</elocation-id><pub-id pub-id-type="doi">10.1016/j.resmic.2019.09.001</pub-id><pub-id pub-id-type="pmid">31594671</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosas</surname><given-names>NC</given-names></name><name><surname>Lithgow</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Targeting bacterial outer-membrane remodelling to impact antimicrobial drug resistance</article-title><source>Trends in Microbiology</source><volume>30</volume><fpage>544</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2021.11.002</pub-id><pub-id pub-id-type="pmid">34872824</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samartzidou</surname><given-names>H</given-names></name><name><surname>Mehrazin</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Benedik</surname><given-names>MJ</given-names></name><name><surname>Delcour</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cadaverine inhibition of porin plays a role in cell survival at acidic pH</article-title><source>Journal of Bacteriology</source><volume>185</volume><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1128/JB.185.1.13-19.2003</pub-id><pub-id pub-id-type="pmid">12486035</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schembri</surname><given-names>MA</given-names></name><name><surname>Blom</surname><given-names>J</given-names></name><name><surname>Krogfelt</surname><given-names>KA</given-names></name><name><surname>Klemm</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Capsule and fimbria interaction in Klebsiella pneumoniae</article-title><source>Infection and Immunity</source><volume>73</volume><fpage>4626</fpage><lpage>4633</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.8.4626-4633.2005</pub-id><pub-id pub-id-type="pmid">16040975</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlundt</surname><given-names>A</given-names></name><name><surname>Buchner</surname><given-names>S</given-names></name><name><surname>Janowski</surname><given-names>R</given-names></name><name><surname>Heydenreich</surname><given-names>T</given-names></name><name><surname>Heermann</surname><given-names>R</given-names></name><name><surname>Lassak</surname><given-names>J</given-names></name><name><surname>Geerlof</surname><given-names>A</given-names></name><name><surname>Stehle</surname><given-names>R</given-names></name><name><surname>Niessing</surname><given-names>D</given-names></name><name><surname>Jung</surname><given-names>K</given-names></name><name><surname>Sattler</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure-function analysis of the DNA-binding domain of a transmembrane transcriptional activator</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>1051</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-01031-9</pub-id><pub-id pub-id-type="pmid">28432336</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Seemann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Prokka</data-title><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/tseemann/prokka">https://github.com/tseemann/prokka</ext-link></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>YT</given-names></name><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>YH</given-names></name><name><surname>Hsueh</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Infections caused by Carbapenem-resistant Enterobacteriaceae: an update on therapeutic options</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>80</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.00080</pub-id><pub-id pub-id-type="pmid">30761114</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamatakis</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Raxml version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies</article-title><source>Bioinformatics</source><volume>30</volume><fpage>1312</fpage><lpage>1313</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu033</pub-id><pub-id pub-id-type="pmid">24451623</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stracy</surname><given-names>M</given-names></name><name><surname>Snitser</surname><given-names>O</given-names></name><name><surname>Yelin</surname><given-names>I</given-names></name><name><surname>Amer</surname><given-names>Y</given-names></name><name><surname>Parizade</surname><given-names>M</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Rimler</surname><given-names>G</given-names></name><name><surname>Wolf</surname><given-names>T</given-names></name><name><surname>Herzel</surname><given-names>E</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name><name><surname>Kuint</surname><given-names>J</given-names></name><name><surname>Foxman</surname><given-names>B</given-names></name><name><surname>Chodick</surname><given-names>G</given-names></name><name><surname>Shalev</surname><given-names>V</given-names></name><name><surname>Kishony</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections</article-title><source>Science</source><volume>375</volume><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1126/science.abg9868</pub-id><pub-id pub-id-type="pmid">35201862</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Struve</surname><given-names>C</given-names></name><name><surname>Bojer</surname><given-names>M</given-names></name><name><surname>Krogfelt</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Characterization of Klebsiella pneumoniae type 1 fimbriae by detection of phase variation during colonization and infection and impact on virulence</article-title><source>Infection and Immunity</source><volume>76</volume><fpage>4055</fpage><lpage>4065</lpage><pub-id pub-id-type="doi">10.1128/IAI.00494-08</pub-id><pub-id pub-id-type="pmid">18559432</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>MJ</given-names></name><name><surname>Petty</surname><given-names>NK</given-names></name><name><surname>Beatson</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Easyfig: a genome comparison visualizer</article-title><source>Bioinformatics</source><volume>27</volume><fpage>1009</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr039</pub-id><pub-id pub-id-type="pmid">21278367</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamma</surname><given-names>PD</given-names></name><name><surname>Goodman</surname><given-names>KE</given-names></name><name><surname>Harris</surname><given-names>AD</given-names></name><name><surname>Tekle</surname><given-names>T</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Taiwo</surname><given-names>A</given-names></name><name><surname>Simner</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Comparing the outcomes of patients with Carbapenemase-producing and non-Carbapenemase-producing Carbapenem-resistant Enterobacteriaceae bacteremia</article-title><source>Clinical Infectious Diseases</source><volume>64</volume><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw741</pub-id><pub-id pub-id-type="pmid">28013264</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamma</surname><given-names>PD</given-names></name><name><surname>Opene</surname><given-names>BNA</given-names></name><name><surname>Gluck</surname><given-names>A</given-names></name><name><surname>Chambers</surname><given-names>KK</given-names></name><name><surname>Carroll</surname><given-names>KC</given-names></name><name><surname>Simner</surname><given-names>PJ</given-names></name><name><surname>Bourbeau</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Comparison of 11 phenotypic assays for accurate detection of Carbapenemase-producing Enterobacteriaceae</article-title><source>Journal of Clinical Microbiology</source><volume>55</volume><fpage>1046</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1128/JCM.02338-16</pub-id><pub-id pub-id-type="pmid">28077701</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Bharathwaj</surname><given-names>M</given-names></name><name><surname>Rosas</surname><given-names>NC</given-names></name><name><surname>Leier</surname><given-names>A</given-names></name><name><surname>Akutsu</surname><given-names>T</given-names></name><name><surname>Webb</surname><given-names>GI</given-names></name><name><surname>Marquez-Lago</surname><given-names>TT</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lithgow</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>DeepBL: a deep learning-based approach for in silico discovery of beta-lactamases</article-title><source>Briefings in Bioinformatics</source><volume>22</volume><elocation-id>bbaa301</elocation-id><pub-id pub-id-type="doi">10.1093/bib/bbaa301</pub-id><pub-id pub-id-type="pmid">33212503</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>R</given-names></name><name><surname>Menzel</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Filtlong</data-title><version designator="v0.2.0">v0.2.0</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/rrwick/Filtlong">https://github.com/rrwick/Filtlong</ext-link></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilksch</surname><given-names>JJ</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Clements</surname><given-names>A</given-names></name><name><surname>Gabbe</surname><given-names>JL</given-names></name><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Cavaliere</surname><given-names>R</given-names></name><name><surname>James</surname><given-names>CE</given-names></name><name><surname>Whitchurch</surname><given-names>CB</given-names></name><name><surname>Schembri</surname><given-names>MA</given-names></name><name><surname>Chuah</surname><given-names>MLC</given-names></name><name><surname>Liang</surname><given-names>Z-X</given-names></name><name><surname>Wijburg</surname><given-names>OL</given-names></name><name><surname>Jenney</surname><given-names>AW</given-names></name><name><surname>Lithgow</surname><given-names>T</given-names></name><name><surname>Strugnell</surname><given-names>RA</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MrKH, a novel c-di-GMP-dependent transcriptional activator, controls Klebsiella pneumoniae biofilm formation by regulating type 3 Fimbriae expression</article-title><source>PLOS Pathogens</source><volume>7</volume><elocation-id>e1002204</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002204</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><data-title>Kraken</data-title><version designator="v0.10.5-beta">v0.10.5-beta</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/DerrickWood/kraken">https://github.com/DerrickWood/kraken</ext-link></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JJ</given-names></name><name><surname>Wang</surname><given-names>LR</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>HM</given-names></name><name><surname>Yan</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Prevalence and characteristics of Ertapenem-resistant Klebsiella pneumoniae isolates in a Taiwanese university hospital</article-title><source>Microbial Drug Resistance</source><volume>17</volume><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1089/mdr.2010.0115</pub-id><pub-id pub-id-type="pmid">21352075</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyres</surname><given-names>KL</given-names></name><name><surname>Wick</surname><given-names>RR</given-names></name><name><surname>Gorrie</surname><given-names>C</given-names></name><name><surname>Jenney</surname><given-names>A</given-names></name><name><surname>Follador</surname><given-names>R</given-names></name><name><surname>Thomson</surname><given-names>NR</given-names></name><name><surname>Holt</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of Klebsiella capsule synthesis loci from whole genome data</article-title><source>Microbial Genomics</source><volume>2</volume><elocation-id>e000102</elocation-id><pub-id pub-id-type="doi">10.1099/mgen.0.000102</pub-id><pub-id pub-id-type="pmid">28348840</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyres</surname><given-names>KL</given-names></name><name><surname>Wick</surname><given-names>RR</given-names></name><name><surname>Judd</surname><given-names>LM</given-names></name><name><surname>Froumine</surname><given-names>R</given-names></name><name><surname>Tokolyi</surname><given-names>A</given-names></name><name><surname>Gorrie</surname><given-names>CL</given-names></name><name><surname>Lam</surname><given-names>MMC</given-names></name><name><surname>Duchêne</surname><given-names>S</given-names></name><name><surname>Jenney</surname><given-names>A</given-names></name><name><surname>Holt</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae</article-title><source>PLOS Genetics</source><volume>15</volume><elocation-id>e1008114</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1008114</pub-id><pub-id pub-id-type="pmid">30986243</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yahav</surname><given-names>D</given-names></name><name><surname>Giske</surname><given-names>CG</given-names></name><name><surname>Grāmatniece</surname><given-names>A</given-names></name><name><surname>Abodakpi</surname><given-names>H</given-names></name><name><surname>Tam</surname><given-names>VH</given-names></name><name><surname>Leibovici</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>New beta-lactam-beta-lactamase inhibitor combinations</article-title><source>Clinical Microbiology Reviews</source><volume>34</volume><elocation-id>e00115-20</elocation-id><pub-id pub-id-type="doi">10.1128/CMR.00115-20</pub-id><pub-id pub-id-type="pmid">33177185</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yigit</surname><given-names>H</given-names></name><name><surname>Queenan</surname><given-names>AM</given-names></name><name><surname>Anderson</surname><given-names>GJ</given-names></name><name><surname>Domenech-Sanchez</surname><given-names>A</given-names></name><name><surname>Biddle</surname><given-names>JW</given-names></name><name><surname>Steward</surname><given-names>CD</given-names></name><name><surname>Alberti</surname><given-names>S</given-names></name><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Tenover</surname><given-names>FC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a Carbapenem-resistant strain of Klebsiella pneumoniae</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>45</volume><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.4.1151-1161.2001</pub-id><pub-id pub-id-type="pmid">11257029</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83107.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ogbunugafor</surname><given-names>C Brandon</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.30.505938" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.30.505938"/></front-stub><body><p>In this study, the authors examine the mechanisms of resistance to carbapenem in <italic>Klebsiella</italic> quasipneumoniae, through a non–carbapenemase mechanism. The evidence – which includes a combination of experimental and computational approaches – is compelling. It offers a set of findings that make a very important contribution to our understanding of not only how antimicrobial resistance evolves, but how to integrate methods and data of different kinds towards understanding a complex evolutionary phenomenon.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83107.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ogbunugafor</surname><given-names>C Brandon</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Yale University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Maddamsetti</surname><given-names>Rohan</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00py81415</institution-id><institution>Duke University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.30.505938">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.08.30.505938v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Treatment history shapes the evolution of complex carbapenem–resistant phenotypes in <italic>Klebsiella</italic> spp.&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and George Perry as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Rohan Maddamsetti (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>You must either provide data on the history of the patient, or substantially reframe the claims made. Currently, while the paper has compelling data and analyses, the central claims are not supported. In general, toning down some of the claims, and making them much more consistent with the data and results (which are strong) are needed.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>The manuscript was very interesting and had a good flow. Apart of the problem with the experimental evolution (Figure 5, lines 193–215):</p><p>– Figure 1B: Please enlarge the font size of the colour key.</p><p>– Figure 1B: What do you mean by: &quot;The outer ring colours indicates the distribution of the sequence type classifications&quot;? Where is the colour code?</p><p>– line 138: &quot;…resistance to we used…&quot; should be &quot;…resistance, we used…&quot;.</p><p>– Figure 3B: Please indicate the region enlarged in 3C.</p><p>– Line 156: Why figure S4?</p><p>– Line 193: What is the phenotype of the ompK36+ strain (before the evolution experiment)?</p><p>– Line 198: What is the B3 population?</p><p>– Line 521: In this experiment you assume that the GFP expression has no effect in our conditions. His is not necessarily true. You can validate this by checking whether you get S=0 when you compare the non–evolved strain with no GFP expression to the one with GFP expression. If this was already done, it is not clear from the text.</p><p>– Line 293: Figure 6E does not exist.</p><p>– Table S7 and S8: The actual location of the mutations is not shown. Please provide the details.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;The evolutionary mechanism of complex carbapenem–resistant phenotypes in <italic>Klebsiella</italic> spp.&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by George Perry (Senior Editor) and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>Please pay close attention to the recommendations from reviewer #2, which include suggestions regarding the use of technical jargon and the use of precise language. It is very important to not further obfuscate genetics understanding which is already confusing to many.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This paper is a valuable contribution to the field of AMR evolution. I have one comment.</p><p>The authors did an admirable job of dissecting the genetic basis of carbapenem resistance. Given the &quot;simple&quot; genetic basis (simple as in explained by 2 loci), I suggest cutting language about &quot;complex&quot; genetic basis or &quot;omnigenic inheritance&quot; because these terms have a specific technical meaning in genetics. &quot;complex traits&quot; are those that are generated by many (hundreds of) loci, and &quot;omnigenic&quot; *specifically* refers to traits in which most of the genome contributes. See the original paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536862/</p><p>Along these lines, perhaps a title like: &quot;<italic>Klebsiella</italic> spp. can evolve carbapenem resistance without carbapenemases&quot;? Something that conveys the main point more precisely.</p><p>Lines 78–80: Cut &quot;Given the omnigenic nature of this type of AMR phenotype&quot; so that the sentence is: &quot;Understanding the details of these evolutionary forces could provide a means to re–sensitize populations of bacteria to carbapenems.&quot;</p><p>Line 90: cut &quot;complex basis again so: &quot;explain the evolution of non–carbepenemase CRE.&quot;</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83107.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>You must either provide data on the history of the patient, or substantially reframe the claims made. Currently, while the paper has compelling data and analyses, the central claims are not supported. In general, toning down some of the claims, and making them much more consistent with the data and results (which are strong) are needed.</p></disp-quote><p>We appreciate the point and have substantially reframed the claims with regard to patient history. This revision is detailed under each of the points made by Reviewer #1.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>The manuscript was very interesting and had a good flow. Apart of the problem with the experimental evolution (Figure 5, lines 193–215):</p><p>– Figure 1B: Please enlarge the font size of the colour key.</p><p>– Figure 1B: What do you mean by: &quot;The outer ring colours indicates the distribution of the sequence type classifications&quot;? Where is the colour code?</p></disp-quote><p>We have made these corrections and have revised the Legend for Figure 1B to clarify:</p><p>“(B) Maximum likelihood phylogenetic tree of 377 publicly available <italic>Klebsiella</italic> genomes shows <italic>K. pneumoniae</italic> and <italic>K. quasipneumoniae</italic> as distinct species. The inner ring colors refer to the country of isolation according to the key and further data is described in Figure supplement 1 and Figure 1- source data 1.”</p><disp-quote content-type="editor-comment"><p>– line 138: &quot;…resistance to we used…&quot; should be &quot;…resistance, we used…&quot;.</p></disp-quote><p>Corrected (now line 136).</p><disp-quote content-type="editor-comment"><p>– Figure 3B: Please indicate the region enlarged in 3C.</p></disp-quote><p>We have revised Figure 3B to indicate the region enlarged in Figure 3C with a black arc line, and clarified the Legend in this regard.</p><disp-quote content-type="editor-comment"><p>– Line 156: Why figure S4?</p></disp-quote><p>Corrected, we have move the figure reference to make it clear why we reference this figure (now Figure 3—figure supplement 2) now Line 152.</p><disp-quote content-type="editor-comment"><p>– Line 193: What is the phenotype of the ompK36+ strain (before the evolution experiment)?</p></disp-quote><p>The ompK36<sup>+</sup>, pNAR1 strain (Lineage B, generation 0) is resistant to penicillin and cephem antibiotics, but susceptible to carbapenem antibiotics. We tested the antimicrobial susceptibility profile before the evolution experiment (Table 1) and compared these values with the evolved strains (Table 3).</p><disp-quote content-type="editor-comment"><p>– Line 198: What is the B3 population?</p></disp-quote><p>We appreciate the point regarding the nomenclature and have revised Figure 5 to include a graphic (Figure 5A) depicting the lineages (A or B, denoting OmpK36 status) and populations (20 populations were evolved in parallel). Population B3 is one of the 20 populations that evolved from lineage B, the ompK36+ lineage.</p><p>We have revised the RESULTS text (Lines 184 onward), citing Figure 5A and explaining which strains are referred to as A2 and B3 (sentence starting Line 189).</p><disp-quote content-type="editor-comment"><p>– Line 521: In this experiment you assume that the GFP expression has no effect in our conditions. His is not necessarily true. You can validate this by checking whether you get S=0 when you compare the non–evolved strain with no GFP expression to the one with GFP expression. If this was already done, it is not clear from the text.</p></disp-quote><p>Thank you for pointing out this out. We have now explained more clearly what we have done in the Methods section.</p><p>We do account for the cost of GFP. We do this by first comparing the ancestor strain (FK688 ∆ompK36pNAR1) to the ancestor-GFP strain and then setting that as fitness = zero. Then, we compared every strain that we are interested into to the GFP strain, and report the fitness of each strain relative to the ancestor. In this way we can obtain information of the relative fitness of each strain, even if the GFP does have a fitness effect.</p><disp-quote content-type="editor-comment"><p>– Line 293: Figure 6E does not exist.</p></disp-quote><p>Corrected.</p><disp-quote content-type="editor-comment"><p>– Table S7 and S8: The actual location of the mutations is not shown. Please provide the details.</p></disp-quote><p>Table S7 and S8 (Figure 5—figure supplement 1 and 2) have been revised to show the position of each SNP and genome modification.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>Please pay close attention to the recommendations from reviewer #2, which include suggestions regarding the use of technical jargon and the use of precise language. It is very important to not further obfuscate genetics understanding which is already confusing to many.</p><p>Reviewer #2 (Recommendations for the authors):</p><p>This paper is a valuable contribution to the field of AMR evolution. I have one comment.</p><p>The authors did an admirable job of dissecting the genetic basis of carbapenem resistance. Given the &quot;simple&quot; genetic basis (simple as in explained by 2 loci), I suggest cutting language about &quot;complex&quot; genetic basis or &quot;omnigenic inheritance&quot; because these terms have a specific technical meaning in genetics. &quot;complex traits&quot; are those that are generated by many (hundreds of) loci, and &quot;omnigenic&quot; *specifically* refers to traits in which most of the genome contributes. See the original paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536862/</p></disp-quote><p>Thanks, and this is very reasonable request. To address the reviewer’s concerns, we have remove the word “complex” from the abstract (Line 37), so it now reads:</p><p>“…could explain the genetic basis of carbapenem-resistance found in many enteric-pathogens.”</p><p>There are no other instances of the word complex or omnigenic in the manuscript.</p><disp-quote content-type="editor-comment"><p>Along these lines, perhaps a title like: &quot;Klebsiella spp. can evolve carbapenem resistance without carbapenemases&quot;? Something that conveys the main point more precisely.</p></disp-quote><p>We have changed the title to incorporate the spirit of the reviewer’s recommendation, removing the word “complex” and including “non-carbapenemase”. The new title:</p><p>“The evolutionary mechanism of non-carbapenemase carbapenem-resistant phenotypes in <italic>Klebsiella</italic> spp.”</p><disp-quote content-type="editor-comment"><p>Lines 78–80: Cut &quot;Given the omnigenic nature of this type of AMR phenotype&quot; so that the sentence is: &quot;Understanding the details of these evolutionary forces could provide a means to re–sensitize populations of bacteria to carbapenems.&quot;</p></disp-quote><p>This has been done (now Line 79), the manuscript now reads:</p><p>“Understanding the details of these evolutionary forces could provide a means to re-sensitize populations of bacteria to carbapenems.”</p><disp-quote content-type="editor-comment"><p>Line 90: cut &quot;complex basis again so: &quot;explain the evolution of non–carbepenemase CRE.&quot;</p></disp-quote><p>We have done this, now Line 90:</p><p>“…which may explain the evolution of non-carbepenemase CRE.”</p></body></sub-article></article>